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Abstract
Background: The present literature review is part of the NNR5 project with the aim of reviewing and updating
the scientific basis of the 4th edition of the Nordic Nutrition Recommendations (NNR) issued in 2004.
Objectives: The overall aim was to review recent scientific data on the requirements and health effects of
vitamin D and to report it to the NNR5 Working Group, who is responsible for updating the current dietary
reference values valid in the Nordic countries.
Methods: The electronic databases MEDLINE and Swemed were searched. We formulated eight questions
which were used for the search. The search terms related to vitamin D status and intake and different health
outcomes as well as to the effect of different vitamin D sources on vitamin D status. The search was done in
two batches, the first covering January 2000March 2010 and the second March 2009February 2011. In the
first search, we focused only on systematic literature reviews (SLRs) and in the second on SLRs and
randomized control trials (RCTs) published after March 2009. Furthermore, we used snowballing for SLRs
and IRCTs published between February 2011 and May 2012. The abstracts as well as the selected full-text
papers were evaluated in pairs.
Results: We found 1,706 studies in the two searches of which 28 studies were included in our review. We found
7 more by snowballing, thus 35 papers were included in total. Of these studies, 31 were SLRs and 4 were
RCTs. The SLRs were generally of good or fair quality, whereas that of the included studies varied from good
to poor. The heterogeneity of the studies included in the SLRs was large which made it difficult to interpret
the results and provide single summary statements. One factor increasing the heterogeneity is the large
variation in the assays used for assessing 25-hydroxyvitamin D concentration [25(OH)D], the marker of
vitamin D status. The SLRs we have reviewed conclude that the evidence for a protective effect of vitamin D is
only conclusive concerning bone health, total mortality and the risk of falling. Moreover, the effect was often
only seen in persons with low basal 25(OH)D concentrations. In addition, most intervention studies leading
to these conclusions report that intervention with vitamin D combined with calcium and not vitamin D alone
gives these benefits. It was difficult to establish an optimal 25(OH)D concentration or vitamin D intake based
on the SLRs, but there are evidence that a concentration of ]50 nmol/l could be optimal. The doseresponse
studies relating vitamin D intake (fortification and supplementation) to S-25(OH)D suggested that an intake
of 12.5 mg/day will increase the serum concentration by 12 nmol/l but this is dependent on the basal
concentration with a response being greater when the basal concentration is low.
Conclusion: Data show that a S-25(OH)D concentration of 50 nmol/l would reflect a sufficient vitamin D
status. Results from this review support that the recommendation in NNR 2004 needs to be re-evaluated and
increased for all age groups beyond 2 years of age. We refer to the total intake from food as well as
supplements, given minimal sun exposure. Limited sunshine, however, does not reflect the situation for the
majority of the Nordic population in the summertime. It should also be emphasized that there are large
differences in results depending on assay methods and laboratories measuring 25(OH)D, adding to the
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uncertainty of determining an appropriate target concentration. Moreover, the doseresponse of vitamin D
on serum 25(OH)D-concentrations is not well established and is dependent on the basal concentrations,
sunshine exposure and dietary intake. We advise that these uncertainties should be taken into account when
setting the final Nordic recommendations.
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T
his literature review is part of the NNR5 project
with the aim of reviewing and updating the
scientific basis of the 4th edition of the Nordic
Nutrition Recommendations (NNR) issued in 2004 (1).
The NNR5 project is mainly focused on a revision of
those areas in which new scientific knowledge has
emerged since the 4th edition with special relevance for
the Nordic setting. A number of systematic literature
reviews (SLRs) will form the basis for the establishment
of dietary reference values in the 5th edition of NNR.
The dietary reference values for vitamin D in the 4th
edition of the NNR are 10 mg/day for the age group 623
months, 7.5 mg/day for 260 years, 10 mg for 61 years and
older, and for pregnant and lactating women 10 mg/day.
The upper level of vitamin D intake for adults is 50 mg/
day (1).
Aims
The overall aim was to review recent scientific data on
requirements and health effects of vitamin D and to
report it to the NNR5 Working Group, who is respon-
sible for updating the current dietary reference values
valid in the Nordic countries. The SLR followed the
guidelines for conducting systematic reviews set by the
working group (2).
The specific objectives of the review on health effects of
vitamin D in human nutrition were to:
1) review the scientific evidence to determine, based on
a set of agreed criteria, dietary reference values for
vitamin D for different life stages (infants, children,
adolescents, adults, elderly and during pregnancy
and lactation),
2) assess the requirement for adequate growth, devel-
opment and maintenance of health of vitamin D,
3) assess the health effects of different intakes/expo-
sures of vitamin D.
Scientific background
In humans, vitamin D is obtained from the diet and
through cutaneous synthesis in the presence of ultra-
violet irradiation supplied by sunlight. Vitamin D is con-
verted to 25-hydroxy-vitamin D [25(OH)D] in the liver
and is transported in the circulation by a vitamin-D-
binding protein, DBP (also named Gc-protein or Gc-
globulin). The 25(OH)D concentration measured in
serum or plasma is considered to be the best marker of
vitamin D status.
The biologically active form, 1,25-dihydroxy-vitamin D
[1,25-(OH)2-D], is formed in the kidneys from 25(OH)D.
1,25-(OH)2-D stimulates bone resorption and intestinal
calcium absorption, leading to an increase in serum
calcium concentration. The synthesis and secretion of
1,25-(OH)2-D is mainly regulated by changes in serum
parathyroid hormone (PTH) concentration, which is
regulated by the serum calcium concentration, as well
as by serum phosphate concentration and by itself.
Fibroblast growth factor 23 (FGF23) is also involved in
the regulation of 1,25-(OH)2-D (3). 1,25-(OH)2-D exerts
its main biological effects via an intracellular vitamin D
receptor (VDR). The VDR has been found in many cell
types. Recent detailed analysis has not confirmed the
presence of VDR in cardiac and skeletal muscle, but there
is an ongoing debate on this issue, as 1,25-(OH)2-D has
specific effects on, that is, muscle cells (4, 5). The 1,25-
(OH)2-DVDR-complex acts as transcription factor in
the target cells. The classical targets are the intestinal
mucosa cells and the skeleton. In the intestine 1,25-
(OH)2-D induces the calcium-binding protein (calbindin)
and the calcium channel TRPV6 (6). In bone tissue, the
role of 1,25-(OH)2-D is complex but it is a strong regu-
lator of receptor activator of NF-kB ligand( RANKL) a
key molecule in osteoclastogenesis (7). Recently, it has
been shown that 1,25-(OH)2-D can be produced from
circulating 25(OH)D locally in other cells than kidney
cells, for example, in osteoblasts. In this way 1,25-(OH)2-
D can exert its effects in an autocrine or paracrine
manner (for review, see the study of Norman and
Bouillon [8]).
1,25-(OH)2-D has important roles in many physiologi-
cal systems beside calcium homeostasis: the immune
system, the pancreatic beta-cells to name a few and has
distinct biological responses in the related cells. Fig. 1
displays some of the roles of 1,25-(OH)2-D in physiolo-
gical systems and the biological responses as well as
diseases and health outcomes that could be related to
vitamin D deficiency (8).
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Vitamin D status and vitamin D sources in the Nordic
countries
Denmark
The vitamin D status in Denmark has been evaluated in
a few studies. Andersen et al. (9) performed a cross-
sectional study in five different European countries, one
of which was Denmark. They showed that 51% of
teenage girls had 25(OH)D concentrations lower than
25 nmol/l and 93% had concentrations lower than 50
nmol/l in the winter. In addition, 17% of elderly women
had concentrations lower than 25 nmol/l and 55%
concentrations lower than 50 nmol/l. The median vitamin
D intake from diet was 2.4 and 3.4 mg in the girls and
women, respectively. Vitamin D supplements were used
by 34% of the girls and 62% of the elderly women. In a
recent study, Thuesen et al. (10) evaluated the vitamin D
status in 6,146 randomly selected individuals aged 3060
years that participated in a health examination in 1999
2001. The overall prevalence of vitamin D deficiency
(25(OH)D B25 nmol/l) and insufficiency (25(OH)DB50
nmol/l) was 13.8 and 52.2%, respectively. A marked
seasonal variation was seen in the 25(OH)D concentra-
tions, the median 25(OH)D concentrations were lowest
in February and highest in August. Estimated dietary
intake of vitamin D ranged between 0.2 and 22.5 mg/
day (median 3.0 mg/day, n6,224). Data on the use of
supplements were not collected and the vitamin D
sources were not explored in this study. Serum 25
(OH)D concentrations were not associated with the
estimated dietary intake of vitamin D. The Pakistanis
are a large immigrant population in Denmark. In a study
in girls, women and men of Pakistani origin, Andersen
et al. (11) showed in a cross-sectional study spanning over
JanuaryNovember that the incidence of severe vitamin
D deficiency was very common. Eighty-one percent of
the girls and 84% of the women had 25(OH)D concen-
trations below 25 nmol/l and 46% of the girls and 40% of
the women were below 10 nmol/l. Sixty-five percent of
the men had 25(OH)D concentrations below 25 nmol/l
and 13% were below 10 nmol/l. Almost all persons had
25(OH)D concentrations below 50 nmol/l. Use of vita-
min-D-containing supplements had a positive association
with S-25(OH)D for both men and women. Dietary
vitamin D intake was 2.2 mg/day in men and 1.7 mg/day
in women. Based on these reports, the vitamin D status in
Denmark seems to be problem both in the native Danish
population but especially in the Pakistanis.
Iceland
In Iceland, cod liver oil is an important and traditional
source of vitamin D, especially for children and the older
generation, presently supplying 48% of total vitamin D
Fig. 1. Overview of vitamin D and its role on physiological systems and the biological responses as well as possible vitamin D-
related diseases. The three columns on the right side, respectively, indicate the following: physiological systems (the six
physiological systems that the essential nutrient vitamin D3 supports by its metabolism to 25(OH)D3 and 1a,25(OH)2D3);
biological responses (examples of biological responses generated by 1a,25(OH)2D3 in the six physiological systems); and vitamin
D-deficient-related diseases (identifies for each system some of the disease states that are associated with an inadequate vitamin
D nutritional status) (8).
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from foods according to the National Nutrition Survey.
Fatty fish and fortified fats are also important sources.
Vitamin D intake varies considerably within the popula-
tion, with 10% of adults having a habitual intake of 53.1
mg/day, while 10% have a habitual intake of ]21.6 mg/day
of vitamin D (12). Supplement use contributes greatly to
this variation. Young adults, aged 1830 years and not
taking supplements, have a mean intake of 3.9 mg/day of
vitamin D, while the same age group taking cod liver oil
has a mean intake of 13.5 mg/day (12). The significance
of supplement use, including cod liver oil, is also reflected
in vitamin D status in Iceland, with serum 25 OHD con-
centrations averaging B28 nmol/l in FebruaryMarch in
adult men and women not taking supplements, compared
with 48 nmol/l for those taking cod liver oil or other
vitamin-D-containing supplements (13). The authors
conclude that supplements are needed for adequate
vitamin D status during winter in northern regions. Ice-
landic food and nutrition recommendations from 2004
advise the use of vitamin D supplements or cod liver oil
(14) and pre-schools commonly supply cod liver oil to
children throughout the year.
Finland
The vitamin D intake and vitamin D status has been
low in Finland in all age groups. The authorities have,
however, introduced fortifications schemes to broaden
the sources of vitamin D in the population. In 2003, the
Ministry for Trade and Affairs, based on simulations,
recommended that all fluid milk products should be
fortified with 0.5-mg vitamin D3/100 g, and all spreads
with 10 mg/100 g (previously 7.5 mg/100 g). The effect of
this fortification has been evaluated in a large population
study of about 650 participants (aged 474 years) with
blood samples and other data from 2002 and 2004. The
median daily intake increased, for example, by 1.8 mg
in 2766 year olds and the increase in the 25(OH)D
concentration was 7.0 nmol/l (15). In those using fluid
milk products, the impact on intake and vitamin D status
was considerable. The main sources were fish/fish pro-
ducts and fortified milk products, the importance of
which is dependent on the age groups. The use of sup-
plements was important as a source of vitamin D in all
age groups (15). There were some groups that were still
at risk  small children, pubescent girls, and young and
middle-aged women. In the Findiet 2007 study, the mean
daily dietary vitamin D intake of women aged 2565
years was 5.2 mg and in 65 to 74-year-old women 6.5 mg,
whereas it was 7.1 and 9.0 mg in the corresponding age
groups for men (16).
In 2010, the National Board of Nutrition increased the
recommendation for fortification to 1 mg/100 g fluid milk
products and for spreads 20 mg/100 g. Moreover, the
authorities (National Board of Nutrition; Institute of
Welfare and Health; Finnish Paediatric Society) recom-
mend since 2011 that children and youths aged 318 years
should take a daily 7.5 mg vitamin D supplement all
around the year, whereas children younger than 3 years
should take a 10-mg daily supplement. Noteworthy is
that vitamin D supplements have been recommended to
children younger than 3 years for decades in Finland,
but it has largely been given only to children during their
first year of life (17) Currently, there are no published
studies in Finland from 2010 to show what the actual
intake and vitamin D status is in the Finnish population.
Regarding ethnic groups, a recent study by Islam et al.
(18) has shown that Bangladeshi women but especially
Somali women has a very low vitamin D status in
Finland.
Norway
The main dietary sources of vitamin D in the Norwegian
population are fatty fish, fortified margarine and butter
and cod liver oil supplements (19). In addition, it is
common to take other vitamin D supplements. The use of
cod liver oil supplements represents a long dietary
tradition in Norway. A nationwide dietary survey found
that 45% of middle-aged women reported cod liver oil
supplement use (20). However, the use of this supplement
has been found to be less among the younger population.
The contribution of cod liver oil supplement to increase
vitamin D intakes in Scandinavia compared to southern
Europe has been described (21). A systematic review
has been conducted by Holvik et al. (22) for available
literature on vitamin D status in Norway. They concluded
that the vitamin D status was sufficient for the majority
in the general population (25(OH)D ]50 nmol/l was
considered as optimal) and that available data suggest
that the vitamin D status in Norway is better than more
southern locations in Europe. In spite of this, some have
insufficient 25(OH)D concentrations, and that vitamin D
status dropped in late winter, also in southern Norway.
Some vulnerable groups were identified, that is, non-
western immigrants and the elderly, especially those living
in nursing homes. A working group on vitamin D in the
Norwegian population, nominated by the National
Council of Nutrition, recommended in their report (19)
an increased fortification of foods, in particular milk, in
order to improve the vitamin D status in the population
including vulnerable groups.
Sweden
The vitamin D intake of the adult Swedish population
was reported in 1998 in the national survey, Riksmaten
(23). The median daily vitamin D intake spanned from
4.0 mg/day in 17 to 24-year-old women to 5.6 mg in
women aged 65 years and older. Correspondingly, the
median daily vitamin D intake in 17 to 24year-old men
was 4.9 mg and 7.0 mg in men older than 65 years. The
main sources were dietary fat, fish and fish products and
Christel Lamberg-Allardt et al.
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fortified milk products. Serum 25(OH)D concentrations
were not measured. A similar survey was performed in
20102011, but the results are not available. Vitamin D
intake and status has been studied in children. In
‘Riksmatenbarn 2003’ (24), a nutrition survey in chil-
dren, found that the mean intake was 6.6, 5.0 and 4.6 mg
in 4-year-olds, 2nd grade and 5th grade, respectively. The
higher intake in the youngest was due to the fact that 21%
of them got vitamin D supplements and 28% ate forti-
fied porridge. In a recent study, Eriksson and Strandvik
(25) found that the mean 25(OH)D concentration was 76
and 68 nmol/l in 4- and 8-year olds, which could be
considered satisfactory. However, a larger percentage (ca.
30%) of the older children had concentrations less than
50 nmol/l than the younger ones (B10%) and 65% of the
older boys and 55% of the older girls had concentrations
B75 nmol/l whereas the numbers were 50 and 40%,
respectively in the younger age groups. The authors state
that the comparably high 25(OH)D concentrations are
due to the fact the children up to the age of five regularly
get vitamin D supplementation.
Research/key questions for vitamin D
The selection of outcomes was based on our knowledge
of the vitamin-D-related scientific literature. The NNR5
Working Group commented on and approved of the
research questions.
The research questions for this systematic review were
as follows:
1) What is the effect of vitamin D from different
sources on serum 25(OH)D concentrations?
2) What is the relationship between 25(OH)D concen-
trations and different outcomes in different popula-
tions and age groups?
3) What is the effect of dietary vitamin D intake on
different outcomes in different populations and age
groups?
4) What is the effect of supplemental vitamin D on
different outcomes in different populations and age
groups?
5) What is the effect of sun or UVB exposure on
different outcomes in different populations and age
groups?
6) What is the UL (tolerable upper intake level) for
vitamin D for different health outcomes in different
populations and age groups?
7) What are the interactions of vitamin D with calcium
intake on different health outcomes in different
populations and age groups?
8) Which is the interaction of vitamin D intake or
vitamin D status with vitamin A intake or vitamin A
status on health outcomes in different populations
and age groups?
Methods
Definitions
The exposures were:
For research question 1: diet/dose; sun exposure/season;
supplements/dose/intervals; obesity; pregnancy/lactation.
For research questions 28: dietary vitamin D, fortified
foods, supplementation and sunlight (natural UV irradia-
tion) exposure, serum 25-hydroxy-vitamin D concentra-
tion, vitamin A intake.
Serum or plasma 25(OH)D-concentration was used as
an indictor of exposure in research questions 28.
The following outcome measures were included:
For research question 1: 25(OH)D. For research ques-
tions 25, 7 and 8: Pregnancy outcomes and growth, bone
health (all fractures, hip fractures, vertebral fractures,
bone mineral density/osteoporosis, bone mass, bone qua-
lity, rickets, osteomalacia, dental health); muscle strength;
falls; all cancers, breast cancer; colorectal cancer; pro-
state cancer; diabetes type I; diabetes type II; multiple
sclerosis; obesity; total mortality; hypertension/blood
pressure; cardiovascular disease (CVD) clinical outcomes;
infections.
Research question 6: calcium metabolism: hypercal-
ciuria, hypercalcemia; soft tissue calcification; renal out-
comes vascular outcomes; mortality; adverse events
reported in RCTs
The following life stages were included: infants,
children, adolescents, adults, postmenopausal women,
elderly, the very old.
Search methods and terms
Two expert reference librarians designed and conducted
the electronic search strategy based on the research
questions provided by the four investigators. The follow-
ing electronic databases were searched: MEDLINE and
Swemed. The search was conducted using medical subject
heading terms (MESH) (see Appendix 1). The search was
done in two batches, the first covering January 2000
March 2010 and the second March 2009February
2011. In the first search, the investigators focused only
on SLRs) and in the second on systematic reviews and
randomized control trials (RCTs) published after March
2009. Furthermore, we used snowballing for SLRs and
RCTs published after that and until May 2012.
Selection of articles/studies
The investigators screened all abstracts from both searches
in pairs, and after that all four investigators made a
common decision on the full-text articles to be acquired
from the librarian. From the batches of full-text articles,
we included those who met the criteria for SLRs. As
regards RCT studies, only studies from Europe and North
America were included. The full-text articles were exam-
ined in pairs and the four investigators made a common
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decision on which articles should be included andwhich to
exclude. Eligible criteria for full-text articles were SLR,
matching the research questions and healthy populations,
not patients or medication, and not meta-analyses.
Quality assessment of studies
Results of systematic reviews and meta-analysis were
quality assessed and evaluated using the NNR5-modified
AMSTAR quality assessment tool and incorporated in
the evidence tables. Quality assessment of the RCTs was
made according to the NNR guidelines (2). The quality
assessment methods of the studies included in the SLRs
differed. The Jadad scale is one of the instruments used to
assess the quality of RCTs and is referred to in some of
the SLRs in this review (26).
Reporting of evidence
The evidence is reported in the evidence tables (Appendix
2) and the summary tables (Appendix 3).
Results
Result of search
In total 1706 abstracts were screened (Fig. 2). The search
was done in two batches, the first covering January 2000
September 2010 and the second covering May 2009 to
February 2011 In the first search, the investigators
focused only on SLRs and in the second on SLRs and
RCTs. Furthermore, the authors used snowballing for
SLRs and RCTs published between March 2011 and May
2012. We primarily identified 108 studies for further
consideration, whereas 1,598 studies were excluded.
Finally, we included 28 studies based on the literature
search and 7 by snowballing, 35 in total. The included
studies are listed in the reference list and the excluded
studies are listed in Appendix 4. The characteristics and
quality of the SLRs and included RCTs are presented in
Appendix 2, respectively. The results of the studies are
presented in specific summary tables 123 (Appendix 3).
Noteworthy is, that two extensive SLRs, Cranney et al.
(27), focusing on the effectiveness and safety of vitamin D,
calcium in relation to bone health and Chung et al. (28)
focusing on vitamin D, calcium and health outcomes,
were performed for the North American vitamin D and
calcium recommendations (29). Chung et al. (28) included
material from Cranney et al. (27), and in some cases built
their conclusions on this earlier evidence report.
The effect of vitamin D from different sources on serum
25-OHD concentrations (Research question 1)
Effect of dietary vitamin D on 25-hydroxy-vitamin D
concentration
We did not identify any SLR on the relationship on
dietary vitamin D from natural sources and 25(OH)
D-concentration.
Effect of fortified foods on 25-hydroxy-vitamin D
concentration
We identified two SLRs on the effect of fortification
(28, 30). For more information, see summary table 1.
First search covering 2000-
september 2010
Abstracts retrieved from electronic,
bibliographics earches: 233
Inclusion criteria: SLR 
Titles and abstract very unlikely
to be relevant: 173
Snowballing March 2011–May
2012 : 7 SLRs 
Inclusion: SLR, RCT
Second search covering May2009-
February 2011. Abstracts retrieved
from electronic,bibliographic
searches: 1473
Inclusion criteria: SLR, RCT
Titles and abstracts very
unlikely to be relevant: 1425
Titles and abstracts that
appeared potentially
relevant, orderedas fulltext
papers: 60
Titles and abstracts that
appeared potentially
relevant, ordered as fulltext
papers: 48
Full papers included: 22 
Full papers included: 6;  2 SLRs 
4 RCTs
Papers excluded: 38
•Not a study question
•Not a SLR 
•Old version(replaced)
•Withdrawn
Papers excluded: 42
•Not a study question
•Not a SLR
• Not a RCT
•Old version (replaced)  
•Withdrawn
•RCT included in snowball
SLR 
•Low rating(D)
Papers included (35)
Fig. 2. Flowchart of study selection.
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Moreover, O’Donnell et al. (31) published a paper based
on part of the same material as Cranney et al. (27), which
is included in this analysis. Chung et al. (28) did not
perform a new SLR but based their conclusions on
Cranney et al. (27).
Cranney et al. (27) included 13 RCTs that studied
the effect of fortified dietary sources of vitamin D on
circulating 25(OH)D-concentrations. Two of the 13 trials
did not provide the vitamin D content of the dietary
source and were excluded, thus 11 studies were included
in the analyses. They studied a total of 1,281 subjects (697
interventions, 584 controls). All trials were carried out in
adults. The quality of 6 out of 11 trials was scored ]3 on
the Jadad scale (26).
The vitamin D dietary interventions included fortified
milk, nutrient dense fruit and dairy-based products, high
vitamin D diet, fortified orange juice, fortified cheese and
fortified bread. The only RCTwith a factorial design had
two other intervention groups that included an exercise
program and a combined program of exercise and
nutrient dense products. The type of vitamin D adminis-
tered was vitamin D3 in eight trials and was not specified
in three. The vitamin D intake was 525 mg/day. Seven
trials also specified the calcium content within the dietary
intervention. The duration of the intervention ranged
from 3 weeks to 24 months. Compliance was reported in
four trials and was stated to be 85%.
Meta-analysis was conducted to quantify the effects of
dietary sources with vitamin D with/without calcium
versus placebo or calcium on serum 25(OH)D concentra-
tions. Seven of the 11 included trials that reported (or
provided sufficient data to calculate) the absolute change
in total 25(OH)D or 25(OH)D3 concentrations were
included in the meta-analysis.
Combining all seven trials that investigated the effect
of food fortification or dietary sources of vitamin D with
or without calcium versus control was not possible due
to heterogeneity of the treatment effect. However, the
individual weighted mean differences demonstrated a
clear trend toward a significantly higher absolute change
in serum 25(OH)D concentration in the treatment group
versus the control.
The positive direction of the treatment effect of dietary
interventions with foods fortified with vitamin D was
consistent. Those trials with low baseline 25(OH)D
concentrations (i.e. B50 nmol/l) demonstrated a greater
percent increase in 25(OH)D concentrations at the end of
study compared to trials with higher baseline 25(OH)D
concentrations (i.e. 50 nmol/l). The authors stated that
observations from such indirect comparisons need to be
interpreted cautiously due to differences in baseline
characteristics of the study populations, the bioavailabil-
ity of the vitamin D in the various food sources and the
different measures of serum 25(OH)D used.
Cranney et al. (27) concluded that
Eleven of the thirteen identified trials on food
fortification and circulating 25(OH)D provided the
vitamin D content (525 mg) of the dietary source.
Most trials used dairy products as the source of
fortified foods. Food fortification with vitamin D
resulted in significant increases in serum 25(OH)D
concentrations with the treatment effect ranging
from 15 to 40 nmol/L. The combined effect of
fortified food from two trials with vitamin D3 doses
equivalent to 1012 mg/d was 16 nmol/L (95% CI
12.9, 18.5). It was not possible from these trials to
determine if the effect of food fortified with vitamin
D on serum 25(OH)D concentrations varied by age,
BMI or ethnicity.
Black et al. (30) performed an SLR based on 16 RCTs
from 15 publications of which 8 were included in the
Cranney et al. report (27). Five studies scored B3 on the
Jadad scale and the rest scored ]3(26). Compliance rate
was reported in 10 studies, which is important in food-
based studies, but not included in the Jadad scale. The
heterogeneity among the studies was high. The authors
did not distinguish between vitamin D3 and vitamin D2 in
the analyses. The authors concluded that
foods fortified with vitamin D increased circulating
25(OH)D concentrations in a dose-dependent man-
ner. In addition they concluded that the treatment
effect was higher in studies using doses ]10 mg/d, in
studies performed at latitudes 40 degrees and where
baseline 25(OH)D concentrations were less than 50
nmol/l. Moreover, the authors calculated that a
mean individual daily intake of about 11 mg vitamin
D from fortified foods increased serum 25(OH)D
concentrations by 19.4 nmol/l on an average corre-
sponding to an average 1.2 nmol/l increase for each
1 mg vitamin D ingested.
Effect of supplementation on 25-hydroxy-vitamin D
concentration
We identified two SLRs (27, 32), for details see summary
table 2. Chung et al. (28) did not perform a new SLR
but based their conclusions on Cranney et al. (27). They
included further analyses of dose response.
Cranney et al. (27) analyzed the effect of vitamin D
supplementation on circulating 25(OH)D concentrations
in different age groups, and the the result are shown
below.
Infants. Seven trials included term infants. Four trials
used vitamin D2, vitamin D3 was used in one and in three
trials no information was given on the form of vitamin D.
Most trials were of lower methodological quality. The
authors concluded that
one trial suggested that 5 mg of vitamin D2 may
not be enough to prevent vitamin D deficiency,
in some infants residing at northern latitudes. A
dose-response was noted in this same trial (2.5, 5,
10 mg/day). Consistent responses to vitamin D
Vitamin D Nordic Nutrition Recommendations
Citation: Food & Nutrition Research 2013, 57: 22671 - http://dx.doi.org/10.3402/fnr.v57i0.22671 7
(page number not for citation purpose)
supplementation were noted across the seven trials,
and some trials suggested that infants, who are
vitamin D deficient, may respond differently and
require higher doses of vitamin D.
Pregnant women and lactating mothers. Six small trials
of vitamin D supplementation in pregnant or lactating
women were included. Three trials used vitamin D2 and
three used vitamin D3. All trials were of low methodo-
logical quality. The authors concluded that
2590 mg/d of vitamin D2 and 25 mg/d of vitamin D3
resulted in significant increases in serum 25(OH)D
concentrations in lactating mothers and in cord
blood. One trial found that supplementation of
lactating mothers with 25 mg of vitamin D2 during
winter months did not increase serum 25(OH)D
concentrations in the infants.
Children and adolescent populations. The authors found
four trials that examined the effect of vitamin D on
25(OH)D in children or adolescents with doses ranging
from 5 to 50 mg of vitamin D3/day in three trials or 10 mg
of vitamin D2 in one trial. The study quality was rated
]3 in three trials on the Jadad scale (26). The authors
concluded that
there were consistent increases in 25(OH)D concen-
trations ranging from 8 nmol/L (with 5 mg of
vitamin D3), 16.5 (with 15 mg) to 60 nmol/L (50 mg).
Premenopausal women and younger men. Ten small trials
included premenopausal women and younger males.
Three trials compared vitamin D2 to vitamin D3 in
healthy young adults. Doses of vitamin D3 ranged from
15 to 250 mg/day and for vitamin D2 the doses were 100
mg/day or 1,2502,500 mg for one dose. The methodolo-
gical quality of eight of the 10 trials was poor. The
authors concluded that
Three trials found that vitamin D2 and D3 in healthy
adults may have different effects on serum 25(OH)
D concentrations. Vitamin D2 appeared to have a
smaller effect on serum 25(OH)D, which may have
been due to more rapid clearance and/or different
metabolism than vitamin D3. One trial compared
2500 mg vitamin D2 orally versus injection and
found a greater variability in response with the
intramuscular preparation. A dose-response effect
was noted in those trials that used multiple doses of
vitamin D3.
Postmenopausal women, older men, and elderly
populations. Forty-four trials were conducted exclu-
sively in postmenopausal women and older men. Four-
teen of these were performed in elderly populations living
in long-term care or nursing homes. One trial was in early
postmenopausal women. Doses ranged from 2.5 to 1,000
mg/day of vitamin D3 and 225 mg vitamin D2/day. In three
studies, single doses of 2,5007,500 mg as injections were
used. One trial was conducted in African American
women. The methodological quality was ]3 in 24 trials.
One trial found that wintertime declines in 25(OH)D
concentration were prevented with 12.5 mg of vitamin D3
daily. A dose response with increasing doses of vitamin
D3 was noted. The authors also performed a meta-
analysis of 16 of the 44 trials in postmenopausal women,
older men, and elderly populations that investigated the
effect of oral vitamin D supplementation with or without
calcium versus no treatment, placebo or calcium on
serum 25(OH)D concentrations. They concluded that
treatment effect of oral vitamin D3 supplementation
increases with increasing doses. Meta-regression
results demonstrated a significant association be-
tween dose and serum 25(OH)D levels. The meta-
regression results suggested that 2.5 mg/d of vitamin
D3 will increase the serum 25(OH)D concentrations
by 12 nmol/L. This suggests that doses of 1020 mg
daily may be inadequate to prevent vitamin D
deficiency in at-risk individuals. Vitamin D3 doses
of 17.5 mg daily or more significantly and consis-
tently decreased serum concentrations of PTH
in vitamin D deficient populations. Given the
limitations in the measurement of 25(OH)D con-
centrations and the lack of standardization and
calibration, it is difficult to suggest precise recom-
mendations for adequate intakes, especially since
optimal levels of serum 25(OH)D have not been
defined.
Chung et al. (28) further analyzed the effect of vitamin D
supplementation on changes in serum 25-OHD concen-
tration based on the results from Cranney et al. (27).
They plotted the net changes in serum 25(OH)D con-
centration against the doses of vitamin D supplementa-
tion using data from 26 RCTs with 28 comparisons in
adults. Only RCTs of daily vitamin D3 supplementation
(doses ranged from 5 to 125 mg/day) alone or in com-
bination with calcium supplementation (doses ranged
from 500 to 1,550 mg/day) that provided sufficient data
for the calculations were included in the plot. The studies
had varied compliance rates in the vitamin D intake;
limited or no adjustment for skin pigmentations, calcium
intake, or background sun exposure; different vitamin D
assay methodologies and measurement variability. They
stated that these factors increased the heterogeneity and
limited the usefulness of an overall summary estimate for
an intake dose response in serum 25(OH)D concentra-
tion. Chung et al. (28) concluded that
a relationship between increasing doses of vitamin
D3 with increasing net change in 25(OH)D concen-
tration was evident in both adults and children, that
the dose-response relationships differed depending
on study participants’ serum 25(OH)D status (540
vs. 40 nmol/L) at baseline, and depending on
duration of supplementation (53 vs. 3 months).
Vitamin D2 supplementation was more commonly
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used in RCTs of infants and pregnant or lactating
women, than vitamin D3 supplementation. Results
showed that supplementation of vitamin D2 signifi-
cantly increased 25(OH)D concentrations in infants,
lactating mothers and in cord blood.
Cashman et al. (32) included 44 RCTs in their systematic
review. In the analyses, priority was given to data from
winter-based RCT (n12) performed at latitudes higher
than 49.5 degrees N. Six of the 12 RCTs were included in
Cranney et al. (27) and had a Jadad score ]3 (26), the
rest were not quality assessed but were included in the
final IoM report (29). The authors concluded that
A combined weighted linear model meta-regression
analyses of natural log total vitamin D intake (diet
and supplemental vitamin D) versus achieved serum
25(OH)D-concentration in winter produced a curvi-
linear relationship. Use of non-transformed total
vitamin D intake data (maximum 35 mg/d) provided
for a more linear relationship. Although inputting
an intake of 15 mg/d (i.e. the US RDA) into the 95%
lower CI curvilinear and linear models predicted a
serum 25(OH)D of 54.4 and 55.2 nmol/l, respec-
tively, the total average vitamin D intake that would
achieve 50 (and 40) nmol/l serum 25(OH)D was 8.9
mg (2.8) and 12 (6.5) mg/d, respectively. Inclusion
of 95% range in the model to account for inter-
individual variability increased the predicted intake
of vitamin D needed to maintain serum 25(OH)D
]50 nmol/l to 23.25 mg/d.
The authors also stated that
these results should be interpreted with caution
because of the few data points in the analysis.
Vitamin D and different health outcomes (Research
questions 24)
Vitamin D and pregnancy
We found two SLRs on pregnancy-related outcomes and
vitamin D that met our inclusion criteria (28, 33). The
reviews are presented in summary table 3.
Chung et al. (28) evaluated one nested case-control
study of healthy, nulliparous pregnant women (n274)
that were followed from less than 16 weeks of pregnancy
to delivery. Women who subsequently developed pre-
eclampsia had lower adjusted mean 25(OH)D concentra-
tions than controls. Early pregnancy maternal 25(OH)D
concentrations below 37.5 nmol/l were associated with
a fivefold increased risk of preeclampsia. Furthermore,
babies of preeclamptic mothers were twice as likely to
have serum concentrations below 37.5 nmol/l compared
with controls. None of these associations varied with race
or ethnicity. The study was rated B.
De-Regil et al. (33) reviewed six randomized trials
including 1,023 pregnant women, in a report that updates
a previous Cochrane report on vitamin D supplementa-
tion and maternal and neonatal outcomes. Intended
maternal outcome measures were preeclampsia, gesta-
tional diabetes and vitamin D status at term. Infant
outcome measures were preterm birth and low birth
weight. In addition, there were a series of secondary
intended outcome measures, including cesarian sections,
maternal hypertension and Apgar score. Most of the
studies were done in the 1980s while one was from 2008
and the dose of vitamin D given on a daily basis ranged
from 20 to 30 mg. Three trials also included high doses in
one of their arms: two of them used a single dose of 5,000
mg in the third trimester and one gave 15,000 mg twice
during pregnancy. Five of the studies, including 623
women supplied vitamin D alone while one study of 400
women gave vitamin D in combination with calcium.
None of the included studies reported on gestational
diabetes or preterm birth. Preeclampsia was only re-
ported in the one study giving both calcium and vitamin
D, and found no difference in risk between the women
receiving supplements compared with the placebo group.
The authors’ conclusions were as follows:
The use of vitamin D supplementation during preg-
nancy improves vitamin D concentrations as mea-
sured by 25-hydroxyvitamin D at term. However,
the clinical significance of this finding is yet to
be determined as there is currently insufficient
high quality evidence relating to the clinical effects
of vitamin D supplementation during pregnancy.
Good quality studies are needed to determine the
usefulness and feasibility of this intervention as a
part of routine antenatal care.
Vitamin D and growth
One SLR (28) was identified evaluating seven interven-
tions and two observational studies on vitamin D and
growth in newborns, infants, or children. The review is
presented in summary table 4. Two interventions included
in the review, where pregnant women in India received
15,000 mg in the 7th and 8th months of pregnancy, were
the only intervention trials reporting statistically sig-
nificant effects of vitamin D supplements on growth.
The studies were rated C as important aspects of the
methodology were not reported. Dietary vitamin D in-
takes of these mothers were estimated to be less than 0.7
0.9 mg/day. A British trial of 126 Asian women receiving
25 mg/day during the third trimester reported no effects
on birth weight or length even though there was an
insignificant reduction in the number of low birth-weight
infants in the intervention group. Similarly, no significant
effect was demonstrated by French, Chinese, or Austra-
lian trials. All of these trials were rated C for methodo-
logical quality except for the British trial which was rated
B. Two cohort studies were also evaluated, one British
and one Australian. Neither study showed significant
associations between maternal serum 25(OH)D and
growth of the offspring. The authors are cautious in their
conclusions regarding the evidence on vitamin D related
to growth, citing lack of methodologically solid studies.
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Chung et al. (28) also reviewed the relationship between
vitamin D and calcium and growth. They found one C-
rated study from India comparing vitamin D and calcium
supplementation in women in their third trimester to no
supplementation. Infants of the women receiving supple-
mentation were significantly heavier.
Vitamin D and bone health
Rickets. We identified two SLRs that met our inclusion
criteria (28, 34). For the results of the studies see
summary table 5.
Chung et al. (28) built on and updated the AHRQ-
Ottawa evidence-based report of Cranney et al. (27),
reviewing concentrations of 25(OH)D related to estab-
lished vitamin-D-dependent rickets in infants and young
children. As an updated search did not identify any new
studies, they simply referred to Cranney et al. (27). In 6
of the 13 studies reviewed, mean or median 25(OH)D-
concentration in children with rickets was B27.5 nmol/l,
whereas it was between 30 and 50 nmol/l in the other
studies. Most studies were conducted in developing
countries with low calcium intake. Low calcium intake
can influence the relationship between 25(OH)D and
rickets, and the 25(OH)D threshold for rickets in
populations with high calcium intake (e.g. North Amer-
ica) is unclear. The Cranney et al. (27) report thus
concluded:
There is fair evidence for an association between
low serum 25(OH)D and established rickets, regard-
less of assay type (RIA, CPBA, HPLC). There is
inconsistent evidence to determine if there is a
threshold concentration of serum 25(OH)D above
which rickets does not occur.
In a Cochrane review by Lerch and Meissner (34), the
aim was to evaluate the effects of interventions on the
prevention of nutritional rickets in term-born children.
The review was limited to studies performed in the last
50 years. Only four trials were included and in two of
them no rickets occurred. The reference was placebo or
no intervention. In a Turkish trial, vitamin D showed a
reduced risk of rickets compared to no intervention. In a
Chinese trial, a combined intervention of vitamin D and
calcium supplementation and nutritional counseling re-
duced the risk of rickets compared to no intervention.
They conclude:
There are only few studies on the prevention of
nutritional rickets in term born children. Until new
data become available, it appears sound to offer
preventive measures (vitamin D or calcium) to
groups of high risk, like infants and toddlers;
children living in Africa, Asia or the Middle East
or migrated children from these regions into areas
where rickets is not frequent.
Fractures. We identified three systematic reviews that
met our inclusion criteria (27, 35, 36). For the results of
the studies see summary table 6.
The Cochrane review by Avenell et al. (35), comprising
postmenopausal women and men over 65 years of age,
concluded that based on available RCTs, it appears
unlikely that vitamin D alone is effective in preventing
hip fracture, vertebral fracture, or any new fracture.
However, a significant reduction in the incidence of hip
fracture in those receiving vitamin D (dose 1020 mg/day)
and calcium versus placebo or no treatment was found.
Subgroup analysis showed a significant reduction in the
subgroup of institutional residents but not in community
dwellers. However, the difference between the two sub-
groups was not statistically significant. The reduction in
incidence of non-vertebral fractures was not significant
in those given vitamin D and calcium. However, in the
subgroup analysis on residential status, a statistical
significant effect was found in the institutional residents’
subgroup but not in community dwellers. There was no
reported effect of vitamin D and calcium on clinical
vertebral fracture. Avenell et al. (35) reported on the
scientific quality on nine different items with scores from
0 to 2. No overall score was given.
The SRL by Vestergaard et al. (36) mainly refers to
Avenell et al. (35) described above. In addition, the results
from the DIPART study (37) are referred to. In this
patient-based pooled analysis of seven major vitamin D
fracture trials with 68,500 participants, no significant
effect of vitamin D alone compared to placebo/no
vitamin D was found for any fracture or hip fracture
(doses of vitamin D 1020 mg/day). However, the overall
risk of fracture was reduced in those given combined
supplementation with vitamin D and calcium compared
to placebo/no vitamin D. The risk of hip fracture was
hazard ratio (HR) 0.84, 95% CI 0.701.01, later corrected
to HR 0.83, 95% CI 0.690.99 due to a coding error in the
original publication, conf. BMJ 2010; 340:b5463). One of
the studies included in DIPART included a drug review
in those receiving vitamin D and calcium. Additional
analysis excluding this study from the pooled analysis
attenuated markedly the effect of vitamin D and calcium
on hip fractures but not on all fractures. Vestergaard
et al. (36) also reported on the results from an RCT
published in 2010 (38) in 2,258 women, aged 70 years or
older. A single high dose of vitamin D3 (12,500 mg) mg or
placebo was given orally once a year over a period of 35
years. Vitamin D3 significantly increased the risk for any
fracture compared with placebo. In addition, the inci-
dence of falls was significantly increased in the vitamin
D3 group compared to placebo. The increased incidence
of falls was most prominent in the first 3 months after
dosing with vitamin D3. Vestergaard et al. (36) concluded
that ‘concerning fracture prevention in postmenopausal
Christel Lamberg-Allardt et al.
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women, vitamin D plus calcium is likely to be beneficial,
whereas vitamin D alone is unlikely to be that’.
The SLR by Chung et al. (28) included and updated
the Cranney et al. (27) evidence-based report and most of
the results are presented/specified in the Cranney report.
When we refer to the Chung et al. (28), this also includes
the Cranney et al. report (27).
It was concluded that based on observational studies,
the evidence was inconsistent for an association between
serum 25(OH)D and the risk of fractures. Combining the
results from 13 RCTs intervening with vitamin D2 or D3
(with or without additional calcium supplementation), a
non-significant reduction in total fractures was found.
Studies intervening with vitamin D alone showed no
effect on fracture incidence by meta-analyses. However,
meta-analyses of studies intervening with vitamin D3 (10
20 mg/day) plus calcium, showed a reduction in the risk of
total fractures and hip fractures. In a subgroup analysis,
a significant effect was only present in institutionalized
elderly. It was stated that one possible explanation for
this was that the studies in institutionalized elderly
achieved on average a higher 25(OH)D concentration at
the end of the study than the studies in community
dwellers. The combined result for studies with higher S-
25(OH)D at follow-up (]74 nmol/l) was a significant
reduction in total fractures, which was not the case for
studies achieving B74 nmol/l. Cranney et al. (27) stated
that this should be interpreted with caution as 25(OH)
D was only determined in subsamples and there was
variability in measurement methods.
None of the trials in the meta-analysis were performed
in premenopausal women.
Cranney et al. (27) concluded that
Vitamin D3 combined with calcium is effective in
reducing fractures in institutionalized populations,
whereas the evidence for community dwellers is less
strong.
The Cranney et al. (27) report was updated in the Chung
et al. (28) report by a new literature search, and a new
RCT reporting on fracture showing no effect of an
intervention with vitamin D2 alone versus placebo was
identified. They also identified an RCT quality rated B,
performed in women aged 1735 years, reporting that 20
mg vitamin D/day combined with a daily supplementation
of 2-g calcium compared to placebo reduced the risk of
stress fracture from military training.
Bone mineral density and bone mineral concentration. We
identified two systematic reviews that met our inclusion
criteria (28, 39). For the results of the studies, see
summary table 7. In addition, we identified one RCT in
the second search (40).
Chung et al. (28) included the Cranney et al. (27)
evidence-based report, and most of the results are
presented and specified in the Cranney et al. (27) report.
When new data were identified in the update made by
Chung et al. (28), this is mentioned in the text and/or in
the summary in table 7.
Cranney et al. (27) addressed whether specific con-
centrations of S-25(OH)D were associated with bone
health outcomes in infants, older children and adoles-
cents, pregnant and lactating women, and postmenopau-
sal women and elderly men. They also addressed the
evidence regarding the effect of vitamin D supplementa-
tion on bone density in women of reproductive age and
postmenopausal women and elderly men. Moreover, they
also reported on the association between S-25(OH)D and
S-PTH. Details are given in the summary tables (sum-
mary table 7). They state the following:
Infants. There was fair evidence for an inverse relation
between S-25(OH)D and S-PTH at low concentrations of
25(OH)D. A threshold may exist around 27 nmol/l. The
evidence for an association between specific concentra-
tions of 25(OH)D and bone mineral content (BMC) was
inconsistent.
Older children and adolescents. No studies assessed the
relation between 25(OH)D concentration and fracture.
There was fair evidence for an inverse relation between
25(OH)D and s-PTH concentrations. The plateau of
PTH concentration ranged from 25(OH)D concentra-
tions of 3083 nmol/l. They also concluded that there was
fair evidence for 25(OH)D concentration being asso-
ciated with a change in bone mineral density (BMD)/
BMC. However, results from two RCTs did not consis-
tently confirm that vitamin D supplementation had an
effect. Moreover, they referred to a Finnish RCT (41) in
228 adolescent girls published after they had done their
systematic search. The intervention was two doses of
vitamin D3 (5 and 10 mg daily) compared to placebo. In
per protocol analyses, they reported positive effects on
BMC where mean S-25(OH)D 50 nmol/l was achieved
in the intervention groups. The results were not statisti-
cally significant in the intention to treat analysis. In a
cohort study, maternal vitamin D status was weakly
related to whole body and spine BMC in children aged 9
years. In a Danish RCT among Pakistani immigrants
with very low vitamin D status at baseline, BMD was
unaffected by a one-year intervention with 10 or 20 mg/
day vitamin D versus placebo.
Pregnant and lactating women. During pregnancy, there
was fair evidence for a negative association between
25(OH)D and S-PTH concentrations, but insufficient
evidence for a relation between 25(OH)D concentration
and change in BMD. One good cohort study found no
relationship between 25(OH)D concentration and BMD
during lactation.
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Postmenopausal women and older men. In five RCTs and
three cohort studies, no association between 25(OH)D
concentration and BMD or bone loss was found. A
significant association between 25(OH)D concentration
and bone loss was found in four cohort studies, most
evident at the hip sites. The evidence for a relationship
between 25(OH)D concentration and BMD in the
lumbar spine was weak. An association between 25(OH)
D concentration and BMD was suggested in six case-
control studies, and the association was most consistent
for femoral neck BMD. They conclude:
There was discordance between the results from
RCTs and the majority of observational studies that
may be due to the inability of observational studies
to control for all relevant confounders. Based on
results of the observational studies, there is fair
evidence to support an association between serum
25(OH)D and BMD or changes in BMD at the
femoral neck. Specific circulating concentrations of
25(OH)D below which bone loss at the hip was
increased, ranged from 3080 nmol/L.
Effect of vitamin D supplementation on bone density in
women of reproductive age and postmenopausal women and
elderly men. Cranney et al. (27) concluded that there
was good evidence for vitamin Dcalcium supplementa-
tion leading to a small increase in spine, femoral neck,
total hip, and total body BMD. Based on available
studies, it was less certain that vitamin D supplementa-
tion alone has an effect on BMD.
In a Cochrane review by Winzenberg et al. (39)
including data up to autumn 2009 (6 RCTs, 541 subjects
receiving vitamin D, and 343 placebo), the objective was
to ‘determine the effectiveness of vitamin D supplemen-
tation for improving bone mineral density in children’.
The dose administered ranged from 3.3 daily to 350 mg/
week. Overall, they did not find any statistically sig-
nificant effect of vitamin D supplementation on total
body BMC, hip BMD, or forearm BMD, whereas a small
effect on lumbar BMD was suggested. No statistically
significant difference was found between studies using a
high or low dose of vitamin D. The difference in effects
between studies with high and low baseline S-25(OH)D
studies was not statistically significant (total body BMC,
p0.09 for difference), although in studies with partici-
pants with low S-25(OH)D (5 35 nmol/l), a significant
effect of supplementation was found for total body BMC
and lumbar BMD.
They concluded that
These results do not support vitamin D supplemen-
tation to improve bone density in healthy children
with normal vitamin D levels, but suggest that
supplementation of deficient children may be clini-
cally useful. Further RCTs in deficient children are
needed to confirm this.
We also identified one new Danish RCT by Mølgaard
et al. (40) with rating B. In this double-blinded RCT,
221 Danish girls aged 1011 years were randomized to
take vitamin D3 (5 or 10 mg) or placebo over 1 year.
Overall, the intervention had no effect on BMC or BMD
(total body and lumbar spine). Compared to the some-
what similar study by Viljakainen et al. (41), which only
included girls from September to March (and which
found an effect in the compliance controlled analysis), the
current study included girls throughout the year.
Vitamin D and dental health
We only found one, C-rated, SLR (42) (see summary
table 8) including several nutrients with the endpoint
being periodontal disease. Only one of the included
original papers was on vitamin D. In this cross-sectional
study, those in the lowest quartile of 25(OH)D concen-
tration had higher clinical attachment loss compared to
those in the highest quintile. The authors conclude that
‘the relationship between vitamin D and periodontal
disease in elderly is unknown and not well researched’.
Vitamin D and falls
We identified seven SLRs (27, 28, 4347), the results of
which are presented in the summary table 9. The defi-
nition of ‘falls’ and ‘falling’ varied among the included
trials. It should be noted that the trials included in the
different SLRs were mainly the same but with some
variation due to inclusion and exclusion criteria and
timeframes.
Chung et al. (28) included and updated the report by
Cranney et al. (27), and most of the results are presented
and specified in the Cranney report. This report included
two additional RCTs related to vitamin D and falls.
Chung et al. (28) concluded that these reports did not
change the conclusion made by Cranney et al. (27).
Cranney et al. (27) evaluated the association of 25(OH)
D concentrations with falls in postmenopausal women
and elderly men. One RCT, three prospective cohorts and
one case-control study were included in their analyses.
The subjects included in the studies were elderly men and
women. The RCT and the cohort studies were of good
quality and the case-control of fair quality. The authors
concluded that
There is fair evidence of an association between
lower serum 25(OH)D concentrations and an in-
creased risk of falls in institutionalized elderly.
PTH may be an important confounder. One study
suggested a specific serum 25-(OH)D concentration
of 39 nmol (l below which fall risk is increased.
Cranney et al. (27) also asked ‘What is the evidence
regarding the effect of supplemental vitamin D on falls in
postmenopausal women and elderly men?’ A total of 14
trials in 16 publications were included, 12 of which were
RCTwith a parallel design and 4 using a factorial design.
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Eleven of the RCTs had a Jadad score ]3 and the score
of the factorial studies was less than three (26). Vitamin
D was given by injection in two studies. Oral vitamin D
was given as vitamin D3 in all but one study. Oral vitamin
D was given without calcium in three trials. Meta-
analyses were conducted using data from the 12 RCTs.
Oral vitamin D did not reduce the risk of falls in
comparison to placebo or calcium. Oral vitamin D with
calcium showed a reduction in falls as compared to
placebo or calcium. Injectable vitamin D2 did not reduce
the risk of falls in comparison to placebo. The authors
summarized that the combined results from 12 trials
(N14,101) demonstrated a small reduction in falls with
vitamin D2/D3 (oral or injectable)9calcium. In the two
factorial design trials, one demonstrated a significant fall
reduction in postmenopausal women taking vitamin D3
plus calcium (whereas the other trial did not show a
reduction in falls in elderly individuals taking vitamin
D2). Moreover, the authors summarized that the results
from trials examining the effect of supplemental vitamin
D on falls are consistent, with 12 of the 14 trials
demonstrating a non-significant reduction in falls. How-
ever, when combining RCTs (by an intervention method),
there is inconsistent evidence regarding the effect of
supplemental vitamin D on falls. The combination of
12 trials of either oral or injectable vitamin D2/D39
calcium did demonstrate a small reduction in fall risk.
Combination of eight RCTs of oral vitamin D2/D3 sup-
plementation with calcium showed a reduction in fall
risk, whereas four RCTs of oral vitamin D3 alone did not.
Subgroup analyses showed a significant reduction in falls
upon combining trials of postmenopausal women only.
Sensitivity analyses showed a significant reduction in falls
when combining: (i) RCTs that explicitly defined falls and
the method of fall ascertainment; and (ii) those in which
the allocation concealment was unclear. However, com-
bining trials by degree of compliance and loss to follow-
up did not result in significant reductions Cranney et al.
(27) concluded that ‘there is inconsistent evidence that
supplemental vitamin D reduces falls in postmenopausal
women and older men’.
Kalyani et al. (43) included 10 RCTs performed
in older adults for a systematic review on vitamin D
treatment for the prevention of falls. Vitamin D3 was used
in six studies, vitamin D2 in three studies and alfacalcidiol
(a synthetic analog) in one study. The methodological
quality of the studies was good in general. In pooled
analysis, vitamin D (5 25 mg/day) resulted in 14% fewer
falls than calcium or placebo. According to this, SLR the
following subgroups had significantly fewer falls: com-
munity-dwelling (aged B80), adjunctive calcium supple-
mentation, no history of fractures or falls, duration
longer than 6 months, vitamin D3, and a dose of 20 mg
or greater. Meta-regression demonstrated no linear asso-
ciation between vitamin D dose or duration and treat-
ment effect. Post-hoc analysis including seven additional
studies (17 in total) without explicit fall definitions
yielded smaller benefit and more heterogeneity but found
significant intergroup differences favoring adjunctive
calcium over none. The authors concluded that ‘vitamin
D treatment effectively reduces the risk of falls in older
adults’.
Cameron et al. (44) studied interventions for prevent-
ing falls in older people in nursing care facilities and
hospitals and included 41 trials (25,422 participants).
Five trials tested the effect of vitamin D supplementation
on falls. The quality of the studies was generally good.
Pooled data from the four studies with 4,512 participants
that provided falls rate data show a statistically signifi-
cant reduction in the rate of falls. Pooled data from all
five studies with 5,095 participants did not show a
reduction in the risk of falling. The authors stated that
caution may be required with interpretation of these
pooled data because of statistical and clinical hetero-
geneity. Two studies investigated vitamin D3 and calcium
and one vitamin D2 in combination with calcium. Two
studies compared vitamin D plus calcium to calcium and
showed a significant reduction on rate of falls but no
reduction in risk of falling. Generally, the baseline serum
25(OH)D concentrations were low in four of these
studies. The authors did not distinguish between trials
including or not including calcium. The authors concluded
that ‘vitamin D supplementation is effective in reducing
the rate of falls in nursing care facilities’.
Gillespie et al. (45) included 13 RCTs focusing on the
prevention of falls in older people living in the community.
Thirteen studies (23,112 enrolled participants) evaluated
the efficacy of vitamin D supplementation, either alone or
with calcium co-supplementation for fall prevention. Two
studies contained multiple intervention arms. The overall
analysis of vitamin D versus control did not show a
statistically significant difference in the rate of falls or risk
of falling. A subgroup analysis showed no significant
difference in either rate of falling or risk of falls in trials
recruiting participants with higher falls risk or trials not so
doing, and no significant difference in effect size between
the subgroups in either analysis. The rate of falls was
significantly reduced in trials with participants with lower
25(OH)D concentrations but not in participants not
selected. There was a significant difference between these
two subgroups with a greater reduction in rate of falls in
the subgroup of trials only recruiting participants with
lower 25(OH)D concentrations. The authors did not
distinguish between trials including or not including
calcium. The authors’ conclusion was
Overall, vitamin D does not appear to be an
effective intervention for preventing falls in older
people living in the community, but there is provi-
sional evidence that it may reduce falls risk in people
with low vitamin D levels [25(OHD)].
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Michael et al. (46) published an SLR on primary-care-
relevant interventions on prevention of falling in older
adults. It included nine trial of vitamin D supplementa-
tion. Five of these included only women and the pro-
portion of women in the others was 5180%. Five trials
were conducted in populations defined as high risk
because of recent falls or vitamin D deficiency. The
remaining four studies used populations that were
unselected except for ages 65 years or older. All studies
were rated as fair quality. The daily oral doses of vitamin
D in the intervention ranged from 2.5 to 25 mg/day
(median: 20 mg). One study provided a single intramus-
cular injection of 15,000 mg of vitamin D. Two studies
evaluated vitamin D2 and the remaining studies evaluated
vitamin D3. Six trials included calcium supplements with
vitamin D. The control groups ranged from no interven-
tion to placebo or calcium supplements only. Vitamin D
with or without calcium was associated with a 17% (CI:
1123%) reduced risk of falling during 636 months of
follow-up. Trials of vitamin D with calcium compared
with no treatment or placebo did not support any added
benefit of calcium.
The authors concluded that
There is strong evidence that several types of
primary care applicable falls interventions (i.e.
comprehensive multifactorial assessment and man-
agement, exercise/physical therapy interventions,
and vitamin D supplementation) reduce falls among
those selected to be at higher risk for falling.
Murad et al. (47) found 26 trials of moderate quality that
enrolled 45,782 participants, the majority of which were
elderly and female to evaluate the existing evidence on
vitamin D use and the risk of falls. Eight studies used
vitamin D2 and 18 vitamin D3 with or without calcium.
In 24 studies, vitamin D was given orally and intramus-
cularly in the remaining two. The results indicated that
vitamin D use was associated with a statistically sig-
nificant reduction in the risk of falls. This effect was more
prominent in subjects who were vitamin D deficient at
baseline and in studies in which calcium was co-adminis-
tered with vitamin D. The quality of evidence was low
to moderate because of heterogeneity and publication
bias, 19 studies were rated high and seven were low. The
authors concluded that
vitamin D combined with calcium reduces the risk
of falls. The reduction in studies without calcium co-
administration did not reach statistical significance.
The majority of the evidence is derived from trials
enrolling elderly women.
Vitamin D and muscle strength or function
We identified two SLRs (48, 49) that included the effects
of vitamin D on muscle strength, which are presented in
the summary table 10.
Stockton et al. (48) included 17 studies. Inclusion
criteria included randomized RCTs involving adults, who
were older than 18 years of age. The quality of the studies
was assessed on the PEDro scale and a median score of 8
out of 10 (range 410; mode 8) was found. The trials used
a variety of vitamin D supplementation regimes. Six trials
compared vitamin D alone with placebo, four of which
used vitamin D2, and two used vitamin D3. One study
compared 1,25(OH)2D with placebo. Treatment with a
combination of vitamin D3 and calcium supplements was
used in nine studies. Five studies compared vitamin D
and calcium with calcium alone, three studies investigated
calcium and vitamin D versus placebo and one study
used calcium and vitamin D versus nothing. Finally, one
study investigated vitamin D via sunlight exposure (with
a clearly defined exposed region and a documented daily
exposure time) to usual care. Two studies did not state
baseline 25(OH)D concentration, participants in four
studies had baseline 25(OH)D 50 nmol/l, the mean
baseline 25(OH)D level was 2550 nmol/l in seven studies,
and B25 nmol/l in four studies.
Meta-analysis showed no significant effect of vitamin
D supplementation on grip strength or proximal lower
limb strength in adults with 25(OH)D concentrations
25 nmol/l. Pooled data from two studies in vitamin D
deficient participants (25(OH)D B25 nmol/l) demon-
strated a large effect of vitamin D supplementation on
hip muscle strength. The Authors? conclusions were
vitamin D supplementation does not have a sig-
nificant effect on muscle strength in adults with
baseline 25(OH)D 25 nmol/L. However, a limited
number of studies demonstrate an increase in
proximal muscle strength in adults with vitamin D
deficiency.
Muir et al. (49) included 13 RCTs, of which 8 were
included in the Stockton analyses (48). The authors
focused on the relation between vitamin D and balance,
gait, and muscle strength as outcomes. The average age of
the subjects in the studies was 7894.1 years.
Statistically significant improvements in physical per-
formance were noted in nine studies. Only one study
demonstrated a beneficial effect on balance of a single
large dose of vitamin D. All studies with daily doses of
2025 mg demonstrated beneficial effects on balance and
lower extremity muscle strength. The same vitamin D
doses had beneficial effects in the two general popula-
tions of community-dwelling and older adults in institu-
tional dwellings. Six of the eight studies that showed a
beneficial neuromuscular effect included calcium supple-
mentation in the regimens.
Twelve of the 13 RCTs included in this systematic
review reported mean serum 25(OH)D concentration at
baseline. Ten of these were in the deficiency range (B50
nmol/l) and two studies in the insufficiency range (5075
nmol/l). Ten studies reported mean serum 25(OH)D
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concentrations at the end of the intervention period. In
the intervention groups, three studies reached normal
25(OH)D concentrations with vitamin D supplementa-
tion and achieved improvements in muscle strength, gait,
or balance function. Six studies showed an increase from
B50 nmol to 50 nmol but B75 nmol/l after interven-
tion, and four demonstrated a significant positive effect
on physical function. One study was not able to improve
the low 25(OH)D concentrations with treatment and did
not demonstrate a positive effect on physical function
outcomes. Statistically significant improvements in phy-
sical performance were noted in nine studies. Only one
study demonstrated a beneficial effect on balance of a
single large dose of vitamin D. All studies with doses of
2025 mg/day demonstrated beneficial effects on balance
and lower extremity muscle strength. Vitamin D doses
of 2025 mg had beneficial effects in the two general
populations of community-dwelling and institutional-
dwelling older adults. Six of the eight studies that showed
a beneficial neuromuscular effect included calcium sup-
plementation in the regimens.
Meta-analysis was performed for the outcomes of
balance (body sway, Timed Up and Go (TUG) test),
lower extremity muscle strength (knee extension), and
grip strength without stratification according to dose
or treatment regimen. The summary standardized mean
difference, derived from studies with a total of 207
participants, on postural sway indicating a reduction in
sway. Three studies with a total of 274 participants
showed a decrease in time to complete the TUG test. A
positive gain in knee extension strength was found.
Muir et al. (49) concluded that
vitamin D supplementation in doses of 20 mg to
25 mg/d have a beneficial effect on balance and
muscle strength. An effect on gait was not found,
although the studies that evaluated gait were of
lower methodological quality and used low doses of
vitamin D.
Vitamin D and cancer
We identified four SLRs that meet our inclusion criteria
(28, 5052) regarding vitamin D and cancer.
Total cancer. Two of the identified SLRs presented
data on the relationship between vitamin D and total
cancer (28, 51). Details of the SLRs are given in summary
table 11.
In the report by Chung al. (28), two B-graded RCTs in
addition to two B- and C-graded cohort studies were
included. The findings were sorted by some lifestage
groups, that is, 1950, 5170, and ]71 years, in addition
to postmenopausal women. None of the included studies
showed significant relationships between either total
cancer and serum 25 (OH) D concentrations (the cohort
studies) or supplement intakes (the RCTs, 25 mg/day or
2,500 mg/month). No gender interaction was found.
The IARC report (51) included three original papers
on serum 25(OH)D concentrations and total cancer mor-
tality. No scientific quality of the studies was included.
These were all cohort studies of which one found no
significant relationship between 25(OH)D concentration
and total cancer whereas another study found a signifi-
cant twofold increased risk for cancer deaths in subjects
with 25(OH) D concentrations below 37.5 nmol/l. The
third cohort found that an increment of 25 nmol/l was
significantly associated with 17% reduction in total
cancer incidence and 29% reduction in cancer mortality.
Colon/colorectal cancers. Colon or colorectal cancers
were included in all four of the identified SLRs (28, 50
52) and are summarized in summary table 12. The report
by the World Cancer Research Fund (50) concluded
that
the evidence on vitamin D was inconsistent and
stated that there is limited evidence suggesting that
foods containing vitamin D, or better vitamin D
status, protect against colorectal cancer.
The evidence for a protective effect of intakes of food
containing vitamin D and colorectal cancer was therefore
rated as limited suggestive.
The overall conclusion in the IARC report (51) on
vitamin D and colorectal cancer was that the observa-
tional evidence for an inverse association between serum
25(OH)D concentrations was consistent and persuasive,
however evidence for a causal link is limited due to
possible confounding which is not controlled for. No
scientific quality of the studies was included. The report
states in the overall conclusion, RCTs have ‘not demon-
strated an effect of vitamin D supplementation on
colorectal cancer risk, but due to several issues (doses,
interaction, duration), they cannot be judged as contra-
dictory to the evidence from observational studies either’.
Chung et al. (28) identified one B-rated RCT, one B-
rated cohort study, and five B-rated and two C-rated
nested case-control studies on the relationship between
vitamin D and colorectal cancers. The RCTwas based on
the relationship between vitamin D3 supplementation and
cancer and was conducted among the elderly. This study
reported negative results for supplemental vitamin D3
versus no supplements. The B-rated cohort study in-
cluded in the Chung et al. report (28), found a reduced
risk of colorectal cancer associated with higher concen-
trations of 25(OH)D, that is, concentrations B50 nmol/l
as reference gave adjusted OR at 0.44 (0.200.95) and
0.28 (0.110.68) for levels 5080 and ]80 nmol/l,
respectively. Chung et al. (28) reported that most nested
case-control studies found no significant associations
between 25(OH)D concentrations and risk of colorectal
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cancer incidence or mortality, except for two of the three
B-rated nested case-control studies in women, where
statistically significant trends between higher 25(OH)D
concentrations and lower risk of colorectal cancer were
found. However, no individual quartile of 25(OH)D
concentration had a significantly increased risk of color-
ectal cancer when compared to the reference quartile.
In the SLR by Yin et al. (52), one cohort study was
included and seven nested case-controls. No scientific
quality of the studies was included. The authors’ conclu-
sion was that
the results support that serum 25(OH)D concentra-
tion is inversely related to colorectal cancer risk.
Breast cancer. Breast cancer was included in three of the
identified SLRs (28, 50, 51). Details of the SLRs are
presented in summary table 13.
The overall conclusion in the IARC report (51) suggest
observational evidence of an inverse association
between 25(OH)D and breast cancer, however, the
overall evidence is weak when case-control are not
included in the meta-analysis and the heterogeneity
between studies are large.
No scientific quality of the studies was included.
The Chung et al. (28) report included one B-rated
cohort study and two B-rated nested-case control studies
on the relationship between vitamin D and breast cancer.
The report concluded that studies on vitamin D intake
and risk of breast cancer were generally negative and
points out that studies on 25(OH)D concentrations
and breast cancer risk were very heterogeneous. Chung
et al. (28) concluded that meta-analysis showed a non-
significant protective effect on 25(OH)D concentration in
blood and breast cancer, but based on very heterogeneous
results. One cohort study (NHANES III) assessed 25
(OH)D concentrations and the risk of breast-cancer-
specific mortality, and found a significant decrease in
breast-cancer-specific mortality during 9 years of follow-
up in those with 25(OH)D concentrations 62 nmol/l.
However, the nested case-control studies did not find a
relationship between 25(OH)D and risk for breast cancer
(712 years follow-up time).
The World Cancer Research Fund report (50) eval-
uated both post- and pre-menopausal breast cancer in
relation to vitamin D exposure. However, the data were
either of too low quality, too inconsistent, or the number
of studies too few to allow conclusions to be reached.
Prostate cancer. Prostate cancer was included in three of
the identified SLRs (28, 50, 51). Details of the SLRs are
presented in summary table 14.
The Chung et al. report (28) identified 12 studies, all
nested-case control studies, on the relationship between
vitamin D and prostate cancer in 14 publications. Three
of these were rated B and the rest was rated C in scientific
quality. Ten publications reported no relationship be-
tween 25(OH)D concentrations and prostate risk. One
study, rated C, found an increased risk associated with
the lowest quartile compared with the highest quartile
(B30 compared to 55 nmol/l). This study also found
an increased risk for prostate cancer in men B52 years
but not for the ]51 years old with 540 nmol/l 25(OH)
D concentrations compared with 40 nmol/l. A later
publication, rated C, based on men from the Nordic
countries showed a U-shaped relationship between 25
(OH)D concentrations and prostate cancer risk.
The IARC report (51) concluded that ‘observational
studies have provided evidence for little or no effect of
vitamin D and prostate cancer’. Moreover, the World
Cancer Research Fund report (WCRF, 50) evaluating
vitamin D and prostate cancer concluded that
data were either of too low quality, too inconsistent,
or the number of studies too few to allow conclu-
sions to be reached.
Vitamin D and diabetes
Diabetes type 1. One SLRwas identified on the relation-
ship between vitamin D and diabetes type 1 (53). Five
studies were included, that is, one cohort study rated B
and four case-controls rated B. The overall conclusion in
their work was that
supplementation with vitamin D in early childhood
may offer protection against diabetes type 1, how-
ever, randomized controlled trials are needed to
establish causality.
Details for this SLR are given in summary table 15.
Diabetes type 2. We identified two systematic reviews
(54, 55) and one RCT (56) on the relationship between
vitamin D and risk for diabetes type 2. The papers are
summarized in summary table 16.
Parker et al. (54) included nine studies in their SLR
and meta-analysis. No grading of scientific quality of
the included studies was given. They found an overall
decrease in the prevalence of diabetes associated with
higher 25-(OH)D concentrations. The conclusion in their
work was that ‘high levels of vitamin D were associated
with substantial decreased risk of diabetes type 2 and that
further controlled trails are needed to evaluate causal
associations’.
Pittas et al. (55) included four studies (two graded as
fair quality and two as good) based on three cohorts.
In addition, eight RCTs, three graded as good and five
as fair, were included on this SLR. Pittas et al. (55)
concluded that
the relationship between vitamin D and diabetes
type 2 remains uncertain and that trials showed no
clinical significant effect of vitamin D supplementa-
tion at the dosages given.
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The RCT (56) did not support a protective effect of 20 mg
vitamin D/day on diabetes type 2. We rated this as grade
A in scientific quality. Diabetes was, however, not the
primary outcome in this study.
Vitamin D and multiple sclerosis
No SLR on the relationship between vitamin D and
multiple sclerosis for the general healthy population was
identified in our search or in the additional search on
recent RCTs.
Vitamin D and body weight
We only found one SLR (28) reviewing the relation
between vitamin D and body weight. Three RCTs
intervening with vitamin D alone were identified, and
no effect on body weight was found. Chung et al. (28)
also reviewed two RCTs intervening with vitamin D and
calcium. In the Women’s Health Initiative (methodologi-
cal quality rate B) intervening with 10-mg vitamin D and
1,000-mg calcium (about 36,000 subjects) over 7 years
lead to a statistical but not clinical significant effect (the
weight change was 0.13 kg lower in the intervention
group). In the other, and much smaller RCT (n63), the
intervention group (10-mg vitamin D and 1,200-mg
calcium daily) lost 1 kg more over 15 weeks than the
control group, but the difference was not statistically
significant (methodological quality rate C). For details
see summary table 17.
Vitamin D and total mortality
We identified three SLRs that met our inclusion criteria
(27, 35, 54). Please refer to summary table 18 for details.
In the Cochrane review by Avenell on vitamin D and
fractures (35), they also assessed the effect of interven-
tions with vitamin D on deaths (total mortality) as a
secondary endpoint. Based on 23 trials, the risk ratio
(RR) of death was 0.97 (95% CI 0.931.01) in those given
vitamin D with or without calcium compared to those
given placebo or calcium. However, in those given
vitamin D plus calcium versus placebo or control (14
trials, 54,203 participants), the RR of death was 0.94
(95% CI 0.890.99).
The Cranney et al. report (27) concluded that data
from four cohorts suggest no association between base-
line 25(OH)D concentrations and total mortality, but one
cohort reported a statistically significant inverse trend.
In meta-analyses including four RCTs, (13,899 partici-
pants, supplementation with vitamin D alone) had no
significant effect on all-cause mortality (RR 0.97, 95% CI
0.921.02), and neither did supplementation with vitamin
D and calcium (11 trials, 44,688 persons) result in a
significant reduced mortality (RR 0.93, 95% CI 0.861.0)
although the point estimate was very similar to that
found in Avenell et al. (35).
A Cochrane review (57) reported that intervention
with D3 with or without calcium versus placebo or no
intervention (32 studies, 74,789 participants) resulted in a
6% reduction in total mortality (RR 0.94, 95% CI 0.91
0.98). The effect was only significant in trials giving
vitamin D3 in combination with calcium. However, D3
alone was merely tested out in a quarter of the trials, and
the difference between trials intervening with vitamin D3
alone and trials intervening with vitamin D3 and calcium
was not significant. Significant effects were found in trials
including participants with low vitamin D status (B50
nmol/l) and in studies intervening with daily doses lower
than 20 mg. However, the differences from the other trials
(vitamin D adequacy (RR0.92, 95% CI 0.71.07) and
dose ]20 mg, respectively (RR0.96, 95% CI 0.921.01)
were not statistically significant. Vitamin D2 did not
reduce mortality.
In the discussion, Bjelakovic et al. (57) also refer to a
Swedish cohort study among elderly men. In this study,
both low 25(OH)D-concentrations (B46 nmol/l, 10%
of the men) and high concentrations (98 nmol/l, 5%
of the men) were associated with increased all-cause
mortality (58).
Vitamin D and hypertension/blood pressure
Four SLRs (28, 55, 59, 60) and one RCT (61) on blood
pressure or hypertension outcomes fulfilled our selection
criteria, see summary table 19 for details.
For hypertension, Chung et al. (28) assessed a com-
bined nested case-control study of men from Health
Professional follow-up study (HPFS) and women from
Nurses’ Health study (NHS). This analysis showed a
fivefold incidence of hypertension in men after 4 and 8
years who had 25(OH)D-concentrations below 37.5
nmol/l at baseline compared with those above 37.5, and
sixfold higher than those above 75 nmol/l. Women with
25(OH)D below 37.5 at baseline had also higher in-
cidence of hypertension after 4 years but not 8 years. A
nested case-control study from the NHS2 showed that
after 7 years, women in the three quartiles with baseline
values below 80.5 nmol/l were 5060% more likely to
develop hypertension than those in the highest quartile.
Chung et al. (28) also evaluated the relationship between
combined vitamin D and calcium. The only study that
was included was the Women’s Health Initiative and they
did not find any effect of vitamin D and calcium on the
risk of hypertension.
For blood pressure, Chung et al. (28) included three
trials, one British (grade A), one German (grade B), and
one Indian study (grade B) with different doses of
vitamin D (20 mg daily, a single dose of 2,500 or 3,000
mg every 2 weeks) compared with placebo None of the
studies reported significant differences in diastolic blood
pressure, while systolic blood pressure was decreased by 6
mm Hg in one study of older women who received both
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20 mg vitamin D and calcium compared with calcium
alone. The study of British older adults showed no effect
of a single dose of 2,500 mg compared with placebo. In
both study arms, systolic and diastolic blood pressure
decreased to a similar extent. The Indian study of obese
men (6 weeks of vitamin D, 3,000 mg every 2 weeks)
reported a close to statistically significant increase in
systolic blood pressure in the intervention group.
Witham et al. (59) included 11 RCTs, 3 of which used
vitamin D3 or vitamin D2 as intervention in hypertensive
adults. The studies were reported to be of variable quality.
Two of the studies were included in Chung et al. (28).
Four studies used either 1,25-(OH)2D or synthetic 1-a-
calcidiol, and one UVB-irradiation. Eight studies were
performed in hypertensive patients. Two studies used
vitamin D3 in normotensive subjects and no effect of
supplementation was seen. The authors conclude: ‘We
found weak evidence to support a small [lowering] effect
of vitamin D on blood pressure in studies of hypertensive
patients’.
Wu et al. (60) assessed four RCTs with changes in
blood pressure as outcome, two of which were included in
the Chung et al. review (28). The quality of the studies
was assessed but not reported. One of the additional
studies used 5-mg vitamin D3 and the other 10-mg vitamin
D3 with calcium compared with placebo. They conclude:
Oral vitamin D supplementation may lead to a
reduction in systolic blood pressure but not diastolic
blood pressure. Given the small number of trials and
small but statistically significant reduction in blood
pressure, further studies and required to confirm the
magnitude of the effect of vitamin D on blood
pressure reduction and define optimum dose, dosing
interval, and type of vitamin D to administer.
Pittas et al. (55) conducted a systematic review and meta-
analysis on cardiometabolic outcomes and vitamin D,
including 32 studies on diabetes, hypertension, and blood
pressure. The three cohort studies assessing hypertension
risk were all included in the Chung et al. report, showing
significant associations between lower 25(OH)D concen-
trations and increased risk of hypertension. In addition,
10 RCTs of vitamin D supplementation were assessed in
the review. Of these, three trials were considered of good
quality, five of fair quality, and two of poor quality. Three
studies not included in any of the above-mentioned
systematic reviews, were assessed in this review, and two
of those were rated as good quality. The Women’s Health
Initiative, rated good, combined a low-dose vitamin D
supplement (10 mg/day) with calcium carbonate, the
number of participants being about 36,000. This study
found no effect on self-reported incident hypertension
after 7 years of follow-up while a sub-group analysis
found an increased risk of incident hypertension among
black participants taking the supplements. However,
vitamin D supplement alone was not assessed in this
trial. The two additional trials included in this evaluation
and not included in former reviews reported no signifi-
cant effects of vitamin D supplements on blood pressure.
Neither did the effect on systolic blood pressure differ
between those trials providing higher (25 mg vitamin
D/day) or lower (B25 mg/day) doses. The authors
concluded
A lower 25(OH)D concentration or vitamin D
intake may be associated with higher risk of incident
hypertension and cardiovascular disease.
We included one RCT (61), graded C, which was not
included in the SLRs. The subjects were randomized to
receive either 1,000 mg vitamin D3/week, 500 mg/week, or
placebo. All subjects were given 500-mg calcium daily. No
beneficial effects of the supplements were observed on
blood pressure, while the group receiving 500 mg showed
a slight but significant increase in systolic blood pressure
compared with the placebo group. Mean baseline con-
centrations of 25(OH)D as well as blood pressure were
within normal range in these subjects, and serum
25(OH)D concentration increased from 58 to 140 and
101 nmol/l in the two intervention groups. The authors’
conclusion was
Our results do not support a positive effect of
vitamin D on hypertension. Further studies in
subjects with low serum 25(OH)D levels combined
with hypertension are needed.
Vitamin D and CVD clinical outcomes
Three SLRs of CVD outcomes and serum concentrations
of 25(OH)D met our selection qualifications. These were
Chung et al. (28), Parker et al. (54), and Grandi et al.
(62). A fourth systematic review, Wang et al. (63), focused
on vitamin D supplementation and CVD and one further
review by Pittas et al. (55) analyzed cardiometabolic
outcomes and vitamin D concentrations. See summary
table 20.
Chung et al. (28) focused on vitamin D and CVD. They
included one RCT, one nested case-control study and
one cohort study. The RCT, where almost 2,700 elderly
British community-dwelling men and women received
either placebo or 2,500-mg vitamin D every 4 months,
reported no significant effects on total cardiovascular
deaths, ischemic heart disease, myocardial infarction, or
stroke after 5 years. Still there were fewer cardiovascular
deaths (RR0.84; CI 0.561.10) as well as ischemic heart
disease deaths (RR0.84; CI 0.561.27) in the interven-
tion group receiving vitamin D than in the placebo group.
In contrast, both cohort studies showed significantly
lower risk associated with increased serum concentrations
of 25(OH)D. In the Framingham Offspring Study (FOS),
men and women with serum 25(OH)D concentrations
below 37.5 nmol/l were 5070% more likely to have a
cardiovascular event within the 5.4-year study period,
compared with those with levels between 25 and 37.5
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nmol/l while a multivariate analysis suggested an in-
creased likelihood of cardiovascular events in people with
S-25(OH)D below approximately 50 nmol/l. Similarly,
the nested case control Health Professional follow-up
study (HPFS) reported over two-fold risk in men with
25(OH)D below 37.5 nmol/l and a 60% increased risk
of cardiovascular events in those with concentrations
between 56 and 75 nmol/l compared with those above
75 nmol/l or higher.
Grandi et al. (62) evaluated the prognostic value of 25-
OH-D concentrations for CVD incidence and mortality.
They reviewed seven prospective studies in addition to
the two included in the Chung et al. (28) report. Three
out of five mortality studies reported significant associa-
tions, with one showing a fivefold increase in risk in those
with concentrations in the lowest quartile, below 30.7
nmol/l. However, two large population-based studies
reported no significant effect on cardiovascular mortality.
Mean age was lower in these two studies, or 44.8 and
49.4 years, respectively, compared with the studies report-
ing increased risk, where mean age ranged from 62 to
74 years. Grandi et al. included two additional inci-
dence studies not included in the Chung et al. report, a
New Zealand study of 1,471 postmenopausal women
participating in a calcium supplementation trial, and a
Finnish study of 689 men and women who were followed
for up to 10 years. Neither study demonstrated a sig-
nificant association of S-25(OH)D concentrations with
cardiovascular events. Grandi et al. concluded
Data from prospective studies suggest an inverse
relationship between 25(OH)D and cardiovascular
risk. However, given the heterogeneity and small
number of longitudinal studies, more research is
needed to corroborate a potential prognostic value
of 25(OH)D for cardiovascular disease incidence
and mortality.
Parker et al. (54) evaluated the association between
25(OH)D and the presence of cardiometabolic disorders
including CVD, diabetes, and metabolic syndrome. They
reviewed and meta-analyzed 28 cross-sectional studies,
case-control, cohort and RCTs on cardiometabolic dis-
orders, including 16 studies with cardiovascular event
outcomes and S-35(OH)D concentrations. Two of the
seven additional studies of CVD outcomes not included
in the review by Grandi et al. (62) did not report a
significant association between CVD risk and vitamin D,
four studies showed lower risk and one study of 216
people living in Southern India showed a 60% higher risk
associated with higher S-25(OH)D concentrations. Meta-
analysis of these 16 studies was consistent with a 33%
reduction in the risk of having a cardiovascular disease. The
authors conclude that
Our findings suggest that high levels of vitamin D,
among adult populations, are associated with a
substantial decrease in cardiovascular disease, type
2 diabetes and metabolic syndrome. Interventions
targeting a positive modification of vitamin D
deficiency in adult and elderly populations would
substantially contribute to halting the current epi-
demics of cardio-metabolic disorders. Further con-
trolled trials are needed to evaluate the causal
association between vitamin D levels and cardio-
metabolic disorders.
The systematic review of Wang et al. (63) assessed 17
studies in total out of which 6 were prospective studies
and 4 were interventions on vitamin D with or without
calcium supplementation for the risk of cardiovascular
event outcomes. The quality was assessed but not
reported in the article. None of the four RCTs on vitamin
D supplements were specifically designed for CVD out-
come, and five of the studies were on patients receiving
dialysis. All five studies on haemodialysis patients showed
a lower risk of cardiovascular events in those receiving
vitamin D as did the single study on vitamin D in the
general population. That study assessed the vitamin D
intake and identified CVD endpoints. Supplemental in-
take greater than 20 mg/day was associated with a non-
significant lower risk of CHD mortality RR0.80 (CI
0.571.13). The conclusions of Wang et al. (63) were:
Evidence from limited data suggests that vitamin D
supplements at moderate to high doses may reduce
CVD risk. Further research is needed to elucidate
the role of these supplements in CVD prevention.
The systematic review of Pittas et al. (55) on vitamin D
and cardiometabolic outcomes is an expansion of the
evidence report for the Institute of Medicine decisions
on vitamin D reference intakes (28). They included 32
studies on diabetes, hypertension, and blood pressure
associated with either vitamin D status or intake of
supplements. The quality was assessed but not reported
in the article. These outcomes are evaluated separately
below. Nine cohort studies analyzing CVD outcomes
were also included in the review, seven of these were
rated of good quality. Cardiovascular endpoints included
myocardial infarction, cardiovascular-related death, a
composite cardiovascular endpoint and stroke. All stu-
dies measured 25(OH)D concentrations. Overall, five
out of the nine studies found that lower 25(OH)D
concentrations were associated with increased risk for
incident CVD. Five trials on vitamin D supplementation
were included in the review. None of these reported
a statistically significant effect of vitamin D supplemen-
tation on various cardiovascular outcomes, including
myocardial infarction and stroke. The authors’ conclu-
sion was:
The association between vitamin D status and cardio-
metabolic outcomes is uncertain. Trials showed
no clinically significant effect of vitamin D in the
dosages given. Adequate randomized controlled
trials, conducted in well-defined populations, are
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needed to test the potential role of vitamin D in
primary prevention or therapy. Vitamin D remains
a promising, although unproven, new element in
the prevention or management of cardiometabolic
disease.
Vitamin D and infections
We identified three systematic reviews (28, 64, 65) and
one additional RCT (66) related to vitamin D and
infections that met our selection criteria (see summary
table 21).
Chung et al. (28) assessed a single cohort study from
the NHANES III on infectious disease mortality, strati-
fied by baseline 25(OH)D concentration. No differences
in infectious disease mortality were detected between
quartiles ranging from B44 to 80 nmol/l after 78
years of follow-up.
Yamshchikov et al. (64) assessed 13 trials, 10 of which
were placebo controlled, studying vitamin D for the
prevention or treatment of infectious disease (bacterial,
viral, and parasitical). The included clinical trials demon-
strated substantial heterogeneity in patient demogra-
phics and vitamin D interventions. On the basis of these
heterogeneous studies, the authors conclude:
More rigorously designed clinical trials are needed
for further evaluation of the relationship between
vitamin D status and immune response to infection.
Another systematic review and meta-analysis on S-25
(OH)D concentrations and tuberculosis assessed seven
observational studies, only one of which was in a
European setting (65). All but one of the studies reported
a significant association between low S-25(OH)D and
active tuberculosis. The authors conclude:
Low serum vitamin D levels are associated with
higher risk of active tuberculosis. Although more
prospective studies are needed to firmly establish the
direction of this association, it is more likely that
low body vitamin D levels increase the risk for
active tuberculosis.
Urashima et al. (66) published a double-blinded RCT
of vitamin D supplementation to prevent influenza A
in Japanese school children. This 4-month trial where
430 children aged 615 years were randomized into
two groups, placebo or supplements of 30 mg/day, had
influenza A, diagnosed by medical doctors using a rapid
influenza diagnostic test (RIDT), as primary outcome.
A reduced risk of influenza was observed in the group
receiving 30-mg vitamin D daily, and more prominent in
those who had not been taking other vitamin D supple-
ments (RR0.36; 0.170.78). Influenza A occurred in
18 out of 167 children taking vitamin D, but in 31 of 167
in the control group. No difference was observed in
influenza B. The study was rated C, in part as 25(OH)D
concentrations were not measured.
The effect of sun or UVB exposure on different outcomes in
different population and age groups (Research question 5)
We identified one SLR on the relationship between both
solar and artificial UVB radiation and 25(OH) in blood
(27) (summary table 22). The report was based on eight
RCTs. The overall quality of the trials was rated as low.
This SLR concluded that ‘‘there is fair evidence that
solar and artificial UV-B exposure increase 25
(OH)D levels. The included trials did not address
the issue of whether serum 25(OH)D response is
attenuated in heavily pigmented groups. It was
also not possible, to evaluate the impact of effect
modifiers such as age, ethnicity, seasonality and
latitude’’.
The authors expressed that further research is needed
to clarify the exact doses needed to maintain 25
(OH)D concentrations over time, in the absence of
supplementation.
The UL for vitamin D for different health outcomes in
different population and age groups (Research question 6)
Both Cranney et al. (27) and Chung et al. (28) included
research questions related to this question. See summary
table 23 for details.
Cranney et al. (27) performed an SLR of a total of 22
RCTs to answer if vitamin D supplementation resulted in
toxicity. A total of 22 trials reported data on toxicity-
related outcomes, 21 of which used doses above 10 mg/day.
Only 12 received a rating of 3 on the Jadad scale (26).
An adequate description of allocation concealment was
reported in three trials. Toxicity results from trials with
intakes of vitamin D above current reference intakes
varied and this may have been related to different doses,
baseline characteristics of populations or exposure times.
Most trials excluded subjects with renal insufficiency or
hypercalcaemia, were of small sample size and had short
durations of exposure to vitamin D. Event rates were
low across trials in both the treatment and placebo arms.
The Womens?Health Initiative trial in women aged 5079
years, examined the effect of vitamin D3 10 mg in
combination with 1,000-mg calcium carbonate versus
placebo and found an increase in the risk of renal stones
corresponding to 5.7 events per 10,000 person-years of
exposure The results are complicated by the fact that the
subjects (intervention and placebo) were allowed to take
additional vitamin D supplements up to 15 mg and later 25
mg per day and also calcium supplements up to 1,000 mg.
The authors conclude
that overall, there is fair evidence that vitamin D
supplementation above current reference intakes,
with or without calcium supplementation, was well
tolerated. A significant increase in kidney stones
was observed in one large trial in postmenopausal
women taking 10 mg vitamin D3 with calcium.
The quality of reporting of toxicity outcomes was
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inadequate in a number of the trials, and most trials
were not adequately powered to detect adverse
events.
Chung et al. (28) considered all the RCTs included in
their SLR focusing on a number of health outcomes.
Only 16 out of 63 RCTs reported adverse effects and they
were generally not powered to detect them. Eleven of
these reported at least one adverse effect.
According to Chung et al. (28), RCTs of vitamin D
(doses ranged from 10 to 143 mg, 5,714 IU/day vitamin
D3 or from 125 to 250 mg vitamin D2) and/or calcium
supplementations (doses ranged from 200 to 1,500 mg/
day) reported few cases of gastrointestinal disruption
such as constipation, diarrhea, upset stomach, muscu-
loskeletal soreness, primary hyperparathyroidism, hyper-
calcemia, renal calculi, and craniotabes. However,
comparisons between the intervention groups and the
control groups were not usually reported. One RCT
reported some adverse events that required hospital
admission, including retrosternal pain, a non-ST eleva-
tion myocardial infarction and a transient ischemic
attack (all three cases in vitamin D 20 mg/day plus
exercise training group) and one case of acute cholecys-
titis (in calcium, vitamin D plus exercise training group).
Another RCT reported that ‘there were no significant
differences between the vitamin D and the control groups
in the rate of incident cancer and vascular disease
(ischemic heart disease and stroke)’ (actual data not
provided), and one participant died during the study.
However, these adverse events may or may not be
associated with vitamin D and/or calcium supplementa-
tion in this study.
We have found the following harms reported in some
of the SLRs included in our review. Michael et al. (46)
concluded that on the basis of the nine fair-quality trials
related to falls included in their review, they found no
increase in falls, fallers, or other major adverse events.
Only three trials specifically reported adverse effects 
transient and asymptomatic hypercalciuria or hypercal-
caemia in the intervention group  but no differences in
adverse effects or clinically significant harms, such as
incident kidney stones, cancer, ischemic heart disease, or
stroke. Gillespie et al. (45) found that adverse effects
(hypercalcaemia, renal disease, gastrointestinal effects)
were reported in three trials but none were statistically
significant. One RCT study (38) reported an increased
risk of fracture and falls in those elderly that were given a
single yearly dose of vitamin D corresponding to about
18 mg/day.
Bjelakovic et al. (57) reported that vitamin D3 com-
bined with calcium increased the risk of kidney stones
(RR 1.17, 95% CI 1.021.34), whereas the effect of
vitamin D was not significant on other side effects.
The interactions of vitamin D with calcium intake on
different health outcomes in different population and age
groups (Research question 7)
In general, we were not able to distinguish vitamin D and
vitamin D together with calcium in our systematic
reviews. Thus, this question has been handled within
the other research questions.
The interaction of vitamin D intake or vitamin D status with
vitamin A intake or vitamin A status on health outcomes in
different population and age groups (Research question 8)
We did not find any SLRs on this topic.
Discussion
The aim of this systematic review was to provide a
scientific base for a Nordic recommendation for dietary
intake of vitamin D. We analyzed the literature on the
relationships between vitamin D, 25(OH)D concentration
and different health outcomes. Moreover, we studied the
relationship between vitamin D intake and 25(OH)D
concentration. We focused on published systematic re-
views but included a few RCTs which were published
after the SLRs. Some of the SLRs included both obser-
vational studies as well as RCTs. In the result section, we
did not include the recent American IoM report on
vitamin D and calcium intake from 2010 (29) as it is not
a systematic review. However, we included the SLRs
forming the basis for the IOM report. We focused on
populations in Europe and North America. However, if
other populations were included in the SLRs, we were
generally unable to separate them.
There are some general challenges when reviewing to
establish evidence for the relationship between vitamin D
and health. First, agreement has not yet been achieved
for what is considered an optimal 25(OH)D concentra-
tion, second the relationship between 25(OH)D and
health outcomes are likely to be confounded by diet, in
particular fish intakes, but also physical activity, both of
which are not easily adjusted for in observational studies.
Third, in experimental studies vitamin D and calcium
supplements are often combined, thus the separate effect
of vitamin D supplements can be questioned.
Assessment of vitamin D status
The reliability of the assays for serum/plasma 25(OH)D
measurement has been questioned.
It has been shown in a number of studies that different
assays give different results (e.g. (6770)). In a recent
Swedish study (71), the same samples were analyzed in
three different laboratories. The results showed a large
discrepancy in the concentrations. Thus, it seems fairly
challenging to use the serum 25(OH)D-concentration as
an outcome marker for assessing vitamin D deficiency
and insufficiency as well as using it as an indicator of
exposure.
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Role of UV exposure
Vitamin D is produced in human skin when exposed to
the sun. It is the ultraviolet (UV) radiation in the UV-B
brand, that is, wavelengths between 290 and 315 nm that
are needed for the photo conversion of provitamin D3 to
previtamin D3 to occur in the skin.
At latitudes above 508N, both the qualitative and
quantitative properties of sunlight is not sufficient in
parts of the year for vitamin D production to take place
(72), leading to the so-called vitamin D winter. In
Copenhagen, the vitamin D winter is estimated to start
in mid-November and last until end of February whereas
in Tromsø it is estimated to last 2.5 months longer. In
Helsinki (608N), the length of the vitamin D winter spans
from mid-October to mid-March (73) and in Reykjavik
(648N) from early October to late March. In addition to
latitude and season, the actual vitamin D production in
skin in humans is affected by several individual and
external factors. The ozone layer effectively absorbs UVB
light, and clouds, when completely overcast, can attenu-
ate the UVB radiation as much as 99%. Surface reflec-
tion, especially from snow can however reflect the UVB
radiation up to 95%.
Time spent outdoors, the use of sunscreen, and cloth-
ing also affect the sun-induced vitamin D for individuals
(74). In addition, individual vitamin D status has been
shown to affect the effectiveness of cutaneous vitamin D3
production, so that individuals with initial low levels of
25(OH)D seem to have a lower threshold concentration
for vitamin D production in skin compared to individuals
with higher concentrations (75). The sun-induced vitamin
D production can be up to six times higher in people
with pale skin compared to people with dark skin (76).
The skins ability to produce vitamin D also decreases
with age (77).
A down-regulating mechanism of vitamin D produc-
tion in skin prevents vitamin D toxicity due to prolonged
sun exposure by a photo-degradation of previtamin D3 to
biologically inert isomers (78).
Data available on seasonal variation in 25(OH)D
concentrations in the general population in some Nordic
countries have demonstrated less fluctuation between
summer (79, 80) and winter compared to other compar-
able populations (81). The vitamin D intake in the diet
and common use of supplements is a possible explanation
for this (21). However, in studies from Finland a marked
seasonal variation in S-25(OH)D concentrations has
been observed in adolescents, in adults and in the elderly
(41, 78, 82). A study from Sweden (83) among women
aged 6183 years, an increase from winter until summer
in 25(OH)D concentrations was found to be 38%. In
Iceland, adults who do not take vitamin D supplements
show a marked seasonal variation (13). The magnitude of
the difference in 25(OH)D concentrations between sum-
mer and winter decreases with increasing latitude (75).
Main findings in relation to the research questions
What is the effect of vitamin D from different sources on
serum 25-OHD concentrations? (Research question 1)
Our first question was related to the effect of vitamin D
from different sources on serum 25(OH)D concentra-
tions. We did not find any SLR on the effect of natural
vitamin D sources on 25(OH)D concentration. However,
we are aware of one study in which the effect of edible
wild mushrooms (Cantharellus tubiformis) on 25-OHD-
concentration has been studied (84). In that study, a
portion containing 15 mg vitamin D2/day increased the
25-OHD concentration to the same extent as a corre-
sponding supplement of vitamin D2, from about 30 to
about 45 nmol/l over 3 weeks.
Regarding fortified foods and supplementation, the
SLRs indicated that there is a clear effect of fortified
foods and supplementation on the S-25OHD concentra-
tion. However, it is not easy to conclude what doses are
needed to achieve specific levels of 25-OHD. One SLR
(Black et al., 30) estimated that 1 mg ingested from
fortified foods increased the S-25(OH)D concentration
by 1.2 nmol/l. Two SLRS focused on supplementation
(27, 32). In the SLR by Cashman et al. (32), the authors
focused on studies performed at latitudes higher than
498N, which is applicable for the Nordic countries. Both
SLRs found a positive effect of vitamin D intake,
including fortified foods (27) and supplements on 25-
OHD concentrations. Cranney et al. (27) concluded that
the meta-regression results suggested that 2.5 mg/day of
vitamin D3 will increase the serum 25(OH)D concentra-
tions by 12 nmol/l. This suggested that doses of 1020 mg
daily may be inadequate to prevent vitamin D deficiency
in at-risk individuals. Vitamin D3 doses of 17.5 mg daily
or more significantly and consistently decreased serum
concentrations of PTH in vitamin-D-deficient popula-
tions. However, Cranney et al. (27) concluded that the
increase in S-25(OH)D concentration was higher when
the baseline concentration was low than when it was
high, and also that the increase was larger if the duration
of the study was longer. Cashman et al. (32) included age
groups between 9 and 78 years. Using meta-regression
analyses, they calculated that an average of 9 mg vitamin
D was needed for a population to achieve 50 nmol/l.
However, taking interindividual variation into account in
the meta-regression analysis, 23.5-mg vitamin D/day was
needed for 95% of the population to reach a serum level
]50 nmol/l. However, the authors concluded that these
latter results have to be treated with caution as the
number of data points in the analysis is low.
Cranney et al. (27) considered different age groups.
They concluded that 5-mg vitamin D/day may not be
enough to prevent vitamin D deficiency in some infants at
northern latitudes. A response in 25(OH)D concentration
of vitamin D supplementation was seen in the trials
included.Most of themused vitaminD2. Supplementation
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during pregnancy with either 2590 mg/day vitamin D2
or 25 mg vitamin D3 increased 25(OH)D concentration
both in the mothers and cord blood. Cranney et al. (27)
included one study on supplementation during pregnancy
(85), in which they did not find an effect of 25-mg vitamin
D given to the mother on the infant S-25(OH)D con-
centration. The authors actually performed another 15
week trial in the winter months after that (86) and found
that giving 50-mg vitamin D3/day to the lactating mothers
increased the infants’ S-25(OH)D to almost the same
level as 10-mg vitamin D2/day to the infant  the level
being ca. 70 and 83 nmol/l respectively. This study was
excluded from the Chung analyses as it was regarded not
to be an RCT. Cranney et al. (27) identified four trials in
children and adolescents and found consistent increases
in S-25(OH)D concentrations with different doses: 8
nmol/l with 5-mg vitamin D3/day, 16.5 nmol/l with 15
mg/day and 60 nmol/l with 50 mg/day. In premenopausal
and younger males, a dose effect was noted in those trials
that used multiple doses of vitamin D3. In this age group,
Cranney et al. (27) also compared the effect of vitamin D2
and D3 on S-25(OH)D concentration and concluded that
vitamin D2 appeared to have a smaller effect than vitamin
D3. A dose response was noted in trials in postmeno-
pausal women, older men and in elderly populations in
long-term care or nursing homes. The doses had a large
range, the basal S-25(OH)D concentrations varied and
the assays used were very heterogeneous.
What is the relationship between 25-OHD concentrations/
dietary vitamin D intake/supplemental vitamin D and different
outcomes in different population and age groups? (Research
questions 24)
Three questions were related to the relationship between
25(OH)D-concentrations or dietary vitamin D or supple-
mental vitamin) and different health outcomes. In addi-
tion to RCTs, the SLRs included mostly cross-sectional,
cohort or longitudinal studies. RCTs have been per-
formed only for skeletal outcomes, falls, muscle function
and weight and these have been included in the SLRs. In
some cases, secondary analyses of the RCTs on some
health outcomes have been performed. We found some
evidence for a causal relationship with bone health, falls
and muscle strength, and total mortality. We did not
find evidence for establishing a causal relationship
between vitamin D intake, vitamin D supplementation,
or serum 25-OHD concentration and most other the
health outcomes.
Pregnancy. De-Regil et al. (33) reviewed six randomized
trials including 1,023 pregnant women. They concluded
that there is currently insufficient high-quality evidence
relating to the clinical effects of vitamin D supplementa-
tion during pregnancy. The other SLR (28) included only
one nested case-control study reporting that a 25(OH)D
concentration lower than 37.5 nmol/l was associated with
an increased risk of preeclampsia.
Growth. Seven intervention studies and two observa-
tional studies were included in one SLR (28). The authors
concluded that due to the lack of methodologically
solid studies, they were cautious in their conclusions
about the effect of vitamin D in newborns, infants, and
children.
Skeletal effects. Low 25(OH)D concentration increases
the risk of rickets. The threshold is uncertain, but a num-
ber of the studies suggest increased risk at S-25(OH)D
concentrations B27.5 nmol/l. Many studies were con-
ducted in developing countries with low dietary calcium
intake. Low calcium intake may influence the relationship
between 25(OH)D and rickets, and the 25(OH)D thresh-
old for rickets in populations with high calcium intake is
unclear. It could be added that vitamin D has been used
as a prophylaxis in the Nordic countries for decades,
and the current recommended daily dose of 10 mg seems
to be effective in preventing rickets if the supplement is
given (87).
The data on the relationship between vitamin D and
bone mineral content or bone mineral density are hetero-
geneous. In infants, there is fair evidence for an inverse
relationship between 25(OH)D and PTH at low concen-
trations, whereas the relationship between 25(OH)D and
BMC is inconsistent. In older children and adolescents,
there is fair evidence for 25(OH)D to be associated with
change in BMC/BMD, but RCTs have not consistently
shown an effect of vitamin D supplementation. A
Cochrane review (34) in children found no overall effect
of vitamin D supplementation, but an effect was sug-
gested in populations with low concentrations of 25
(OH)D. There was insufficient evidence for a relation-
ship between 25(OH)D and change in BMD in pregnant
women, and one good cohort study did not find any
relationship between 25(OH)D and BMD during lacta-
tion. Based on observational studies, there is fair evidence
for a relationship between 25(OH)D and BMD or change
in BMD at the femoral neck in the elderly. From
intervention studies it is good evidence that supplementa-
tion with vitamin D combined with calcium leads to
a small increase in spine, femoral neck, total hip, and
total body BMD. Based on available studies, it is less
certain that vitamin D supplementation alone has an
effect on BMD.
It is challenging to describe optimal concentration of
25(OH)D for bone mineral density or bone mineral
content based on available SLRs. In infants, a threshold
around 27 nmol/l might exist for the relationship between
25(OH)D and PTH (27). This threshold was reported as
3083 nmol/l in older children and adolescents (27). The
SLR by Cranney et al. (27) also refers to one RCT among
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adolescent girls reporting an effect of vitamin D inter-
vention to occur at mean levels of 25(OH)D 50 nmol/l,
whereas the Cochrane review by Winzenberg et al. (39)
only reported an effect of vitamin D supplementation
in children with low mean 25(OH)D at baseline (535
nmol/l). In observational studies among the elderly,
the bone loss at the hip was increased at concentrations
of 25(OH)D ranging from 30 to 80 nmol/l in different
studies.
Fracture is the primary skeletal health outcome in
adults. Based on available data, the SLRs concluded that
intervention with vitamin D (dose 1020 mg/day) com-
bined with calcium reduces the risk of total fracture and
hip fracture, whereas intervention with vitamin D alone
has not shown an effect in the doses tested out. Although
a threshold of 74 nmol/l was considered to show a
reduction in total fracture incidence, the variability in
analytical methods and the fact that S-25(OH)D was
assayed only in subsamples, make this threshold unreli-
able. To what extent an intervention with vitamin D and
calcium prevent fracture in non-institutional elderly is
debated. Both the Cochrane review by Avenell et al. (35)
and the Cranney et al. (27) report only found a significant
effect in studies performed in institutionalized elderly,
although the difference between studies performed in
institutionalized and community dwellers was not statis-
tically significant. However, the DIPART study (37)
reported that the effect was found across a wide range
of age (mean age 70 years; range 47107 years).
Although the overall conclusion is that intervention
with vitamin D alone in the doses tested has not been
proven effective in preventing fractures, it could be added
that a British study by Trivedi et al. (88), Jadad score 3
(26) reported that 2,500-mg vitamin D every 4th months
(corresponding to 20 mg/day) compared to placebo,
reduced the risk for any new fracture (OR 0.78 [95%
CI 0.610.99]). On the other hand, the Australian RCT
referred to previously, reported an increased risk of
fracture in those given a single yearly high dose of
vitamin D (38).
Currently, there is also interest in studying the effect
of higher doses of vitamin D: Vital (ClinicalTrials.gov;
NCT01169259), FIND (NCT01463813) and DO-Health
(not registered as yet).
It could be added that a recent Swedish study referred
to in the IOM report found increased risk of fracture in
men with S-25(OH)D below 40 nmol/l (89).
Dental health. Lack of data precludes any conclusion
concerning the relation between vitamin D and dental
health.
Falls. Six SLRs were focused on vitamin D intake or
25(OH)D and falls. There was overall fair evidence that
vitamin D with calcium is effective in preventing falls in
the elderly especially in those with low baseline 25(OH)D
concentrations, both community dwelling and in nursing
care facilities. One SLR concluded that vitamin D was
effective (43). Some but not all SLRs concluded that a
dose greater than 20 mg was effective, in conjunction with
calcium supplementation. One study suggested that
25(OH)D concentrations below 39 nmol/l were associated
with an increased risk of falls.
Muscle function. Two SLRs focused on vitamin and
outcomes related to muscle function in the elderly.
Stockton et al. (48) concluded that vitamin D supple-
mentation does not have an effect when basal 25(OH)D is
greater than 25 nmol/l, but that vitamin D has an effect in
adults with vitamin D deficiency. However, Muir et al.
(49) concluded that vitamin D doses of 2025 mg/day have
beneficial effects on balance and muscle without taking
baseline S-25(OH)D into account. Thus, doses of 2025
mg/day could be beneficial for muscle function in the
elderly, but the information on the effect of lower doses
was scarce.
Cancer. Vitamin D and cancer have been studied in a
number of cohort studies. Some RCTs have been per-
formed but they are secondary analyses of supplemental
studies for the prevention of fractures (88, 90). There
was not consistent evidence for an association between
vitamin D status and total cancer in SLRs including
cohort studies and RCTs. There is some observational
evidence of an inverse association between vitamin D
status and risk of colorectal cancer, however evidence for
a causal relationship are lacking. The evidence for an
inverse association between vitamin D status and breast
cancer risk is weak due to lack of good quality studies
and heterogeneity between studies. There is little or no
evidence for a protective effect of vitamin D on prostate
cancer.
Diabetes and multiple sclerosis. The evidence for a
causal relationship or an association between vitamin D
and type 1 and type 2 diabetes is limited and inconclusive.
Lack of data precludes any conclusion concerning the
relation between vitamin D and multiple sclerosis.
Body weight. There is no clear evidence for vitamin D to
influence body weight development.
Total mortality. Based on the RCTs in the SLRs it is
concluded that vitamin D3 (1020 mg/day) combined with
calcium significantly reduces total mortality. However, it
is uncertain if co-supplementation with calcium is neces-
sary to achieve this effect. It could be added that a recent a
Swedish cohort study among elderly men followed for
around 14 years reported increased all-cause mortality
both in men at the low (B46 nmol/l) and the high end of
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25(OH)D concentrations (98 nmol/l) (58). Moreover, a
recent Danish cohort study among subjects from the
Copenhagen general practice sector including near to
250,000 subjects that were followed for 3 years found a
reverse J-shaped relationship with the lowest mortality at
25(OH)D concentrations of 5060 nmol/l (91).
Hypertension and blood pressure. Evidence from RCTs
reviewed in four SLRs on blood pressure is inconclusive.
Some RCTs detected a small reduction in diastolic blood
pressure, particularly in people with higher baseline
values, while another showed a small reduction in systolic
pressure. All SLRs concluded that there was a need for
further studies to explore this relationship for possible
clinical significance. A recent RCT (61) which was not
included in the SLRs did not support a positive effect of
vitamin D supplementation in conjunction with calcium
on hypertension, intervening with large doses (500 or
1,000 mg/week with 500-mg calcium) in overweight
persons over 1 year.
However, low vitamin D status has repeatedly been
associated with a higher incidence of hypertension as
reviewed in two SLRs. Nested case control studies show
marked reverse associations between incidence of hyper-
tension and 25(OH)D in men and women with baseline
B37.5 nmol/l compared with 37.5 nmol/l and also
compared with those over 75 nmol/l.
Cardiovascular clinical outcomes. Systematic reviews
based on cohorts or case-control studies have repeatedly
found an association between low 25(OH)D concentra-
tions, mostly below 37.5 or 50 nmol/l and an increased
risk of CVD. However, a significant effect of supplemen-
tation on cardiovascular outcomes has not been reported.
The trials in question were all designed for health
outcomes other than CVD.
Vitamin D and infections. The evidence for an effect of
vitamin D on infections is scarce and trials were very
heterogeneous.
What is the effect of sun or UVB exposure on different
outcomes in different population and age groups? (Research
question 5)
The only SLR assessing this question concluded that
there is fair evidence that both solar and artificial UV-B
exposure increase 25(OH)D concentrations. We were not
able to establish a dose response relationship. We did
not find any SLR addressing the effect of sun or UVB
exposure and other outcomes.
Which is the UL (Tolerable Upper Intake Level) for vitamin D
for different health outcomes in different population and age
groups? (Research question 6)
The SLRs did not give any definite answer to this ques-
tion. Chung et al. (28), Cranney et al. (27), Vestergaard
et al. (36), Avenell et al. (35) and Bjelakovic et al.
(57) included adverse effects in their reviews of RCTs.
Vitamin D given with calcium, but not vitamin D alone,
moderately increased the risk of renal stones.
There are some observational studies suggesting that
total mortality is increased at high 25(OH)D concentra-
tions (58, 91). Some studies have reported an increase
in prostate cancer (92) or total cancer (58) at higher
25(OH)D-concentrations. A trial using large yearly doses
of vitamin D reported increased incidence in fractures
and falls in the elderly (38).
Which are the interactions of vitamin D with calcium intake on
different health outcomes in different population and age
groups? (Research question 7)
We were not able to distinguish between the effect of
vitamin D alone and vitamin D together with calcium
on most of the health outcomes. A combination of
vitamin D and calcium seems to be important in the
prevention of fractures, falls, and all-cause mortality
(total mortality).
Which is the interaction of vitamin D intake or vitamin D
status with vitamin A intake or vitamin A status on health
outcomes in different population and age groups? (Research
question 8)
We did not find any SLRs on this topic.
Difference between vitamin D2 and D3 in increasing S-25-
Hydroxy-vitamin D concentration
The difference between vitamin D2 and D3 was not one of
our initial research questions. We, nevertheless, consid-
ered this to be an important topic that has to be included.
Vitamin D2 and D3 supplementation has been reviewed
in a recent SLR by Tripkovic et al. (93). Ten studies were
included in the systematic review and seven studies in the
meta-analysis. The doses, durations and age groups
varied as well as the route of administration. The authors
concluded that vitamin D3 is more efficacious at raising
25(OH)D than vitamin D2. One of the studies (94)
indicated that the effect of vitamin D2 on S-PTH was
very weak in comparison to the effect of vitamin D3.
Overall discussion
Vitamin D can influence numerous biological processes in
the body. In addition to the effects on bone health, it has
been claimed that vitamin D contributes in the preven-
tion of many medical conditions including CVDs, type 1
and type 2 diabetes, some types of cancer, pregnancy
outcome, and infections. And indeed, there is suggestive
evidence for a number of health benefits of vitamin D
and for plausible biological mechanism. For example, the
observation that S-25(OH)D is inversely related to some
types of cancer is supported by a new reanalysis of
a subgroup of participants in the large Calcium and
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vitamin D trial in the Women’s Health Initiative (95) and
associations between lowered risk for cardiovascular
outcomes and higher 25(OH)D concentrations has re-
peatedly been observed. Similarly, higher risk for pre-
eclampsia has been reported in pregnant women with
25(OH)D below 37.5 nmol/l and the risk for low birth
weight may be lowered in at-risk pregnant women by
vitamin D supplementation.
However, the SLRs we have reviewed conclude that the
evidence for a protective effect of vitamin D is only
conclusive concerning bone health, total mortality and
the risk of falling. In addition, most intervention studies
leading to these conclusions report that intervention with
vitamin D combined with calcium and not vitamin D
alone gives these benefits.
Currently, there is a great interest and a high research
activity concerning vitamin D. Although a large number
of studies, including RCTs, have been performed, there
are still many unanswered questions. For example, it is
unclear why combined interventions with vitamin D and
calcium and not interventions with vitamin D alone have
shown an effect on fracture and mortality risk. The
causes for the increased risk of fracture and falling in
those given a large, annual dose of vitamin D are also
unclear (38), and so is the increased risk of mortality
related to high concentrations of 25(OH)D reported in
some studies (58, 91) Observational studies have rather
consistently shown that low concentrations of 25(OH)D
are related to increased risk of CVD. However, re-
analyses of RCTs suggest that calcium supplementation
(also with vitamin D) might increase the risk of myo-
cardial infarction (95).
Although RCTs were emphasized in most of the SLRs,
we would also point out some limitations. When inter-
preting the effect of doses given in RCTs, it is a challenge
that the participants also receive vitamin D from other
sources (diet and UVB-irradiation). In some studies,
participants were also allowed to use personal supple-
ments in addition to study medication. Basically, the
RCTs give information on the effect of the difference in
vitamin D exposure between the intervention group and
the control group. A large difference in exposure may be
difficult to obtain in RCTs. To test out the exposure of
a moderate dose of vitamin D compared to very little
vitamin D might therefore be difficult.
Many chronic diseases develop overmany years, and it is
also a challenge that RCTs in general are performed over
shorter time frames. Whereas RCTs are feasible in testing
out the effect and side effects of interventions with
supplements, the feasibility of RCTs in establishing the
relation between nutrition and disease has been debated
(50).
It was difficult to establish an optimal 25(OH)D con-
centration or vitamin D intake based on the SLRs.
Other considerations
The IoM (29) also considered calcium absorption
together with BMD, rickets and osteomalacia to find a
totality of evidence for an optimal S-25(OH)D concen-
tration. They found a congruence among these outcomes
with no additional benefits of serum concentrations of
25(OH)D higher than 50 nmol/l.
The relationship between S-25(OH)D and S-PTH has
been considered in numerous studies, and based on
some of them the threshold for vitamin D sufficiency
has varied between 25 and 125 nmol/l. Using S-PTH as
an outcome is difficult as the variation is large and
also other factors have an effect on S-PTH. Sai et al.
(96) concluded in a systematic review that ‘vitamin D
insufficiency should be defined as serum 25(OH)D less
than 50 nmol/l as it relates to bone’.
A number of studies have shown an inverse relation-
ship between S-25(OH)D and BMI or adiposity. Some
supplementation studies, but not all, have shown a lower
response in S-25(OH)D in obese persons than in normal
weight subjects. Moreover, weight loss has led to an
increase in S-25(OH)D in some studies. Thus, though no
SLR addressed this subject, there are some indications
that adiposity should be considered a determinant of
S-25(OH)D-concentration (97). However, this does not
suggest that there is evidence that higher intakes are
needed in obese persons than in those with normal
weight.
Limitations
We focused on SLRs and included only a few new RCTs.
We were not able to perform quantitative analyses of the
studies. The quality of the studies included in the SLRs
varied and there was a large heterogeneity among them.
All age groups were not covered and the study duration
in the trials varied greatly. Different age groups were
considered only in relation to bone health.
Study quality
Due to heterogeneity in the studies, it was difficult to
interpret the results and provide single summary state-
ments. The doses of vitamin D differed widely among the
studies. Habitual vitamin D intake was seldom assessed
and the methods for intake assessment varied. The assays
used for the assessment of S-25(OH)D concentration
varied among the studies. The study cohorts consisted
mainly of Caucasians.
Publication bias
Publication bias cannot be ruled out, since relevant
studies were searched in two electronic databases
(MEDLINE and Swemed), and by snowballing for the
last months. Unpublished or ongoing studies were not
identified.
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Authors’ conclusions
Implications for the Nordic setting
Cutaneous synthesis of vitamin D3 is the physiological
route for vitamin D supply. Due to our geographic
situation, this way of supply is turned off for about 35
months during the year. Dietary vitamin D is thus needed
to keep vitamin D status at an acceptable level. The SLRs
that we have reviewed gave insufficient evidence for an
optimal 25(OH)D concentration and corresponding
vitamin D intake levels in relation to most health outcomes.
However, the association between vitamin D status and
skeletal outcomes and the effect of vitamin D supple-
mentation on skeletal outcomes give some information,
while the role of vitamin D without calcium supplemen-
tation on fracture incidence is unclear. Moreover, studies
on the effect of vitamin D supplementation and vitamin
D fortification on 25(OH)D concentrations gives some
information on how to achieve specific concentrations of
25(OH)D. In this respect, the heterogeneity in the results
by the 25(OH)D assays is a formidable problem.
Many studies suggest that there is an increased risk for
rickets in infants and children when S-25(OHD) concen-
tration is B27.5 nmol/l. A threshold for 25(OH)D at
4050 nmol/l has been suggested in the SLRs for the
prevention of falls and fractures in the elderly. Solid
evidence for an optimal S-25(OH)D concentration (or
optimal intake) in children, adolescents and adults was
not found in the SLRs relating to the health outcomes.
However, a S-25(OH)D concentration of 50 nmol/l could
be a reasonable threshold in these age groups also.
The dose-response studies relating vitamin D intake
(fortification and supplementation) to S-25(OH)D sug-
gested that an intake of 12.5 mg/day will increase the
serum concentration by 12 nmol/l but this is dependent
on the basal concentration with response to being greater
when the basal concentration is low. Chung et al. (28)
concluded that doses of 1020 mg/day may be inadequate
to ensure concentrations of 25(OH)D at or above 50
nmol/l in the great majority of individuals in the popu-
lation if the relationship above was used in the calcula-
tions. Cashman et al. (32) using meta-regression analysis
concluded that 50 nmol/l 9 mg vitamin D was needed
on average in the age groups between 9 and 78 years in
the winter. However, 23.5 mg vitamin D/day was needed
to reach a serum level ]50 nmol/l if interindividual
variation was taken into account by inclusion of the 95%
range in the meta-regression analysis. These values have
to be treated with caution as few studies (data points)
were included. Moreover, as these results are based
on group data, the final interpretation is difficult. An
approach with primary data from the studies would
probably have given other results. In the original studies,
there are confounding factors affecting vitamin D status
that have not always been taken into account in the
studies, for instance dietary vitamin D intake and sun-
light exposure. This affects the basal 25(OH) D concen-
trations which again affects the dose-response. Thus, it is
not easy to make extrapolations regarding the actual
dose/intake and a final 25(OH)D concentration. Com-
pliance has not been taken into account in the analyses.
This is important, as a low compliance in an RCT leads
to ‘falsely’ low 25(OH)D concentrations in the non-
complying subjects, therefore increasing the variance in
the data.
For those older than 3 years, a 50 nmol/l target for
S-25(OH)D concentration would probably require an
average intake of 10 mg/day, that is, 50% of a population
may need more, 50% may need less than this value.
Adding 2 SDs to this average intake would cover 97.5%
of the population. Given that 2SD equal 5 mg/day, this
would result in an intake of 15 mg/day. It should be
considered that these values are based on studies
conducted in the winter without any sunlight exposure.
We do not have any data or evidence on the dietary
requirement during the summer months with sunlight
exposure. It may be presumed that less is needed during
this period for most people to reach 50 nmol/l. Vitamin D
is stored for months after summer in the body. However,
it can be debated to what extent dietary recommenda-
tions should assume dermal synthesis during summer,
as outdoor activity with light clothing may not be
universal, particularly not with the frail elderly and the
institutionalized.
The vitamin D requirement for the elderly has to be
given special consideration. The synthesis of vitamin D in
the skin may be reduced and the intestinal absorption of
vitamin D may be lower than in younger persons. Thus,
older people may need more vitamin D than younger
persons. The dose of vitamin D (1020 mg/day) showed
that to reduce the risk of fracture and total mortality is
challenging to translate directly to recommended intake
of vitamin D. The participants in these studies also got
vitamin D from other sources (background intake and
dermal synthesis), and additional calcium was given.
However, it seems reasonable to recommend a somewhat
higher intake in the elderly due to the above-mentioned
reasons.
There was no evidence for a different intake require-
ment in pregnancy and lactation compared with the
general population. There is some concern about the
vitamin D status in obese persons. We did not find any
evidence for different recommendation among ethnic
groups.
An upper tolerable level (UL) was not possible to
establish based on the SLRs. There is some concern that
higher S-25(OH)D concentrations is associated with an
increase in mortality. Notable is that the IoM as well as
the European Food Safety Agency have set the Upper
Tolerable Intake for adults at 100 mg/day (29, 98).
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In conclusion, if 97.5% of the population up to 75
years of age is to maintain the target 50 nmol/l
concentration of 25(OH)D, the corresponding intake of
vitamin D would be 15 mg/day. Higher intakes may be
needed to cover this same percentage in an older
population. Here, we refer to the total intake from food
as well as supplements, given minimal sun exposure.
Limited sunshine, however, does not reflect the situation
for the majority of the Nordic population in the
summertime. It should also be emphasized that there
are large differences in results depending on assay
methods and laboratories measuring 25(OH)D, adding
to the uncertainty of determining an appropriate target
concentration. Moreover, the dose response of vitamin D
on serum 25(OH)D-concentrations is not well established
and is dependent on the basal concentrations, sunshine
exposure and dietary intake.
Implications for research
We have been able to identify some implications for the
research:
1) The role and dose response of sunshine
2) Standardization of serum/plasma 25(OH)D assays
3) Genes regulating the 25(OH)D concentration
4) Bioavailability of vitamin D from different food
sources
5) Vitamin D status and adverse effects, including
mechanisms
6) Vitamin D’s effects on various health outcomes
7) Vitamin D dosing (including food-based), 25(OH)D,
and health outcomes.
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